Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 61
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of Epicardial Adipose Tissue on Infarct Size and Left Ventricular Systolic Function in Patients with Anterior ST-Segment Elevation Myocardial Infarction

  • Gavara Doñate, Jose|||0000-0002-3483-7066
  • Merenciano, Héctor|||0000-0002-1734-0381
  • Llopis-Lorente, Jordi|||0000-0002-3958-8062
  • Molina-Garcia, Tamara
  • Perez-Solé, Nerea|||0000-0003-3527-0337
  • de Dios, Elena
  • Marcos-Garces, Víctor
  • Monmeneu, José V.
  • Lopez-Lereu, María P.
  • Canoves, Joaquim
  • Bonanad, Clara
  • Moratal, David|||0000-0002-2825-3646
  • Núñez, Julio|||0000-0003-1672-7119
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Sanchis, Juan|||0000-0003-0797-8709
  • Chorro, Francisco J.
  • Rios-Navarro, Cesar|||0000-0002-6405-6279
  • Bodi, Vicente|||0000-0001-6425-5828
We aimed to assess the correlation of cardiovascular magnetic resonance (CMR)-derived epicardial adipose tissue (EAT) with infarct size (IS) and residual systolic function in ST-segment elevation myocardial infarction (STEMI). We enrolled patients discharged for a first anterior reperfused STEMI submitted to undergo CMR. EAT, left ventricular (LV) ejection fraction (LVEF), and IS were quantified at the 1-week (n = 221) and at 6-month CMR (n = 167). At 1-week CMR, mean EAT was 31 ± 13 mL/m. Patients with high EAT volume (n = 72) showed larger 1-week IS. After adjustment, EAT extent was independently related to 1-week IS. In patients with large IS at 1 week (>30% of LV mass, n = 88), those with high EAT showed more preserved 6-month LVEF. This association persisted after adjustment and in a 1:1 propensity score-matched patient subset. Overall, EAT decreased at 6 months. In patients with large IS, a greater reduction of EAT was associated with more preserved 6-month LVEF. In STEMI, a higher presence of EAT was associated with a larger IS. Nevertheless, in patients with large infarctions, high EAT and greater subsequent EAT reduction were linked to more preserved LVEF in the chronic phase. This dual and paradoxical effect of EAT fuels the need for further research in this field.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Intracoronary Delivery of Porcine Cardiac Progenitor Cells Overexpressing IGF-1 and HGF in a Pig Model of Sub-Acute Myocardial Infarction

  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Crisóstomo, Verónica|||0000-0003-1740-7029
  • Moscoso, Isabel|||0000-0002-6078-4666
  • Báez-Díaz, Claudia
  • Blanco-Blázquez, Virginia|||0000-0003-1971-919X
  • Gómez-Mauricio, Guadalupe
  • Albericio, Guillermo
  • Aguilar, Susana
  • Fernández Santos, María Eugenia|||0000-0001-9229-0022
  • Fernández Avilés, Francisco|||0000-0001-5501-5275
  • Sánchez Margallo, Francisco Miguel|||0000-0003-2138-988X
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Bernad, Antonio
Human cardiac progenitor cells (hCPC) are considered a good candidate in cell therapy for ischemic heart disease, demonstrating capacity to improve functional recovery after myocardial infarction (MI), both in small and large preclinical animal models. However, improvements are required in terms of cell engraftment and efficacy. Based on previously published reports, insulin-growth factor 1 (IGF-1) and hepatocyte growth factor (HGF) have demonstrated substantial cardioprotective, repair and regeneration activities, so they are good candidates to be evaluated in large animal model of MI. We have validated porcine cardiac progenitor cells (pCPC) and lentiviral vectors to overexpress IGF-1 (co-expressing eGFP) and HGF (co-expressing mCherry). pCPC were transduced and IGF1-eGFP pos and HGF-mCherry pos populations were purified by cell sorting and further expanded. Overexpression of IGF-1 has a limited impact on pCPC expression profile, whereas results indicated that pCPC-HGF-mCherry cultures could be counter selecting high expresser cells. In addition, pCPC-IGF1-eGFP showed a higher cardiogenic response, evaluated in co-cultures with decellularized extracellular matrix, compared with native pCPC or pCPC-HGF-mCherry. In vivo intracoronary co-administration of pCPC-IGF1-eGFP and pCPC-HFG-mCherry (1:1; 40 × 10 6 /animal), one week after the induction of an MI model in swine, revealed no significant improvement in cardiac function.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biomarkers to Improve Decision-making in Acute Heart Failure

  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Núñez-Marín, Gonzalo|||0000-0003-2867-5344
  • Codina, Pau|||0000-0002-2469-5711
  • Núñez, Julio|||0000-0003-1672-7119
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Acute heart failure (AHF) is a complex clinical syndrome that requires prompt diagnosis, risk stratification and effective treatment strategies to reduce morbidity and mortality. Biomarkers are playing an increasingly important role in this process, offering valuable insights into the underlying pathophysiology and facilitating personalised patient management. This review summarises the significance of various biomarkers in the context of AHF, with a focus on their clinical applications to stratify risk and potential for guiding therapy choices.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Anatomy of the Isthmus, Unraveling the Tissue Composition of the Ventricular Tachycardia Diastolic Pathway

  • Bisbal, Felipe|||0000-0002-4843-7063
  • Aranyó, Júlia
  • Iraola-Picornell, Georgina
  • Sanchez-Quintana, Damian
  • Martínez-Falguera, Daina|||0000-0002-9439-0542
  • Sarrias, Axel|||0000-0001-6712-3097
  • Fadeuilhe, Edgar|||0000-0003-0079-224X
  • Bazán, Víctor|||0000-0001-8072-7434
  • Teis, Albert|||0000-0002-4820-0736
  • Rodriguez-Leor, Oriol|||0000-0003-2657-5657
  • Villuendas-Sabaté, Roger|||0000-0001-9110-905X
  • Curiel, Carolina
  • Armengol, Maria Pilar
  • Pey, Irina
  • Roura, Santiago|||0000-0003-4063-9661
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
Background: A protected, slow-conducting diastolic pathway (isthmus) is the electrophysiological hallmark of post-myocardial infarction (MI) re-entrant ventricular tachycardia (VT). Contemporary evaluations of the histologic composition promoting slow, protected conduction during VT are lacking. Objectives: The goal of this study was to compare the histologic characteristics of confirmed VT isthmuses (VTIs) and non-isthmus scar (NIS) in a chronic MI swine model. Methods: One month after non-reperfused anterior MI, nine Landrace X Large White pigs with inducible VT underwent high-density activation mapping to define the diastolic corridor. Radiofrequency lesions were created to guide the ex vivo VTI localization. Tissue transverse samples from the labeled VTI and NIS were obtained for further histologic, immunohistochemical, and RNA-sequencing expression analyses. Results: Compared with NIS, VTI showed significantly higher fatty infiltration (P = 0.012) and lower levels of collagen I (P = 0.053), collagen III (P = 0.043), and collagen volume fraction (P = 0.027); there were no differences in overall fibrotic deposition. VTI exhibited greater vascular density compared with NIS (P = 0.018), with arteries and veins primarily surrounded by preserved cardiomyocytes. Compared with NIS, viable cardiomyocytes and fibroblasts in VTI displayed higher densities of connexin 43 and connexin 40 (P = 0.022 and P = 0.004, respectively), despite no differences in cardiac troponin I, sarcoplasmic/endoplasmic reticulum Ca2-ATPase 2, or vimentin expression. Thirty-six genes, involving pathways related to extracellular matrix remodeling, inflammation, and immune response modulation, were differentially expressed between VTI and NIS. Conclusions: The VTI exhibits a distinct histologic composition and differential gene expression compared with the surrounding NIS. Mid-diastolic activation sites showed increased adipocytic deposition, vascularization, and connexin expression, along with lower levels of collagen I, collagen III, and collagen volume fraction.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tissue characteristics underlying endocardial local impedance subtypes in chronic myocardial infarction

  • Aranyó, Júlia
  • Martínez-Falguera, Daina|||0000-0002-9439-0542
  • Teis, Albert|||0000-0002-4820-0736
  • Fadeuilhe, Edgar|||0000-0003-0079-224X
  • Rodriguez-Leor, Oriol|||0000-0003-2657-5657
  • Bazán, Víctor|||0000-0001-8072-7434
  • Sarrias, Axel|||0000-0001-6712-3097
  • Tebé, Cristian|||0000-0003-2320-1385
  • Villuendas-Sabaté, Roger|||0000-0001-9110-905X
  • Delgado, Victoria|||0000-0002-9841-2737
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Bisbal, Felipe|||0000-0002-4843-7063
Background: Local impedance (LI) mapping is feasible and provides additional tissue characterization of the ventricular tachycardia substrate. Data on tissue composition underlying the LI spectrum are lacking. Objective: To describe the tissue composition underlying different LI subtypes in a chronic myocardial infarction (MI) swine model. Methods: One month after non-reperfused anterior MI, 18 Landrace Large White pigs underwent delayed-enhancement cardiac magnetic resonance (DE-CMR) and endocardial left ventricular (LV) LI mapping. DE-CMR images were post-processed off-line to obtain LV wall thickness, scar subtypes, and border zone (BZ) corridors, and were co-registered with LI maps. Tissue samples were obtained from abnormal LI sites. Results: Low LI zones exhibited more pronounced wall thinning compared to intermediate LI tissue (2.8 ± 0.7 vs 3.8 ± 0.9 mm; P <.001) and correlated with DE-CMR dense endocardial scarring (91.4%) and with epicardial scarring (75% dense and 24% BZ tissue). Intermediate LI tissue exhibited predominantly subendocardial scarring, with more heterogeneous distribution (45% dense, 47% BZ, and 8% healthy tissue) and less epicardial involvement (73% healthy tissue). Most DE-CMR BZ corridors (75.6%) colocalized with intermediate LI tissue. Histologically, tissue from intermediate LI zones displayed less collagen I (P =.008), collagen III (P =.053), and collagen volume fraction (P =.021), and greater vascular density (P =.075), compared to low LI zones. Conclusions: Areas of low LI had a higher proportion of dense, transmural scar and wall thinning compared to intermediate LI areas. DE-CMR BZ corridors colocalized with intermediate LI in most cases. LI subtypes showed distinctive histological composition.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A narrative review of vascular conduits for coronary artery bypass grafting

  • Iraola-Picornell, Georgina
  • Berastegui García, Elisabet|||0000-0002-1766-2970
  • Castells-Sala, Cristina|||0000-0002-7520-5401
  • Martorell, Jordi|||0000-0002-2043-2762
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Muñoz-Guijosa, Christian|||0000-0002-0272-1704
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
Coronary artery bypass grafting (CABG) involves creating new conduits to restore blood flow to the heart. Using autologous vascular grafts presents challenges, including infection risk after vein harvesting, and scarcity of viable vein tissue. Researchers are exploring tissue-engineered vascular grafts (TEVGs), aiming to create optimal small-diameter vascular graft (SDVG).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cytokine Networks and Heart Failure Outcomes, CA125 as a Bridge Between Congestion and Inflammation

  • Santas, Enrique
  • Martí-Martínez, Arancha
  • Villar, Sandra|||0000-0001-8229-6279
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Rodriguez-Borja, Enrique|||0000-0002-0339-6704
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • González, Arantxa|||0000-0001-5986-6528
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Sanchis, Juan|||0000-0003-0797-8709
  • Núñez, Julio|||0000-0003-1672-7119
Inflammation and congestion constitute fundamental mechanisms underlying heart failure (HF). Carbohydrate Antigen 125 (CA125) is a well-established biomarker in HF, primarily associated with congestion, but also it may act as a functional ligand amplifying the inflammatory response in HF. Our aim was to evaluate the potential modulatory effect of CA125 on inflammation, assessed by a set of cytokines (interleukin [IL]-6, IL-10, IL-1β, and tumor necrosis factor [TNF]). We prospectively included 284 patients admitted for acute HF in which cytokines and CA125 were assessed at admission. Study endpoints were all-cause mortality and total HF rehospitalizations. At a median follow-up of 4.2 years (interquartile range: 1.3-7.5), a total of 211 patients (74.3%) died, and 117 patients (41.2%) experienced 249 HF readmissions. In the multivariable analysis, a significant interaction between IL-6 and IL-10 and CA125 was observed for both outcomes (p -value for interactions < 0.05 for all comparisons). Among patients with CA125 > 35 U/mL, both IL-6 and IL-10 showed a positive, linear relationship with the risk of death or HF readmissions. In contrast, we did not find a significant association in patients with CA125 ≤ 35 U/mL. In conclusion, the association between IL-6 and IL-10 with long-term adverse events was significantly modulated by CA125 status, being significantly associated with poor prognosis only when CA125 was upregulated. These findings support a potential modulatory role for CA125 in the inflammatory response in HF.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Characterization of Infarct Size and Remodeling Using CMR and PET in Mice Models of Reperfused and Non-Reperfused Myocardial Infarction

  • Gavara Doñate, Jose|||0000-0002-3483-7066
  • Molina-Garcia, Tamara
  • Ezzeddin, Mustafa
  • Diaz, Ana
  • Perez-Solé, Nerea|||0000-0003-3527-0337
  • Ortega, Maria
  • Marcos Garcés, Víctor|||0000-0001-5565-5547
  • de Dios, Elena
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Ruiz-Sauri, Amparo
  • Rios-Navarro, Cesar|||0000-0002-6405-6279
  • Bodi, Vicente|||0000-0001-6425-5828
Background/Objectives : Unlike post-mortem histopathology, cardiovascular magnetic resonance (CMR) and positron emission tomography (PET) enable longitudinal assessment of structural, functional, and metabolic alterations in preclinical myocardial infarction models. This study aims to describe the temporal evolution of infarct size and systolic function by CMR and glucose consumption via PET, explore their differences in non-reperfused and reperfusion infarction models, and assess their capacity to predict histology-derived infarct size and systolic function at chronic phase CMR. Methods : Two murine models of myocardial infarction were generated using permanent (non-reperfused, n = 8) or transient (reperfused, n = 9) coronary occlusion. CMR and fluorine-18 2-fluoro-2-deoxyglucose PET imaging were performed at baseline and at 1, 7, and 21 days post-infarction to quantify infarct size, systolic function, and myocardial glucose metabolism. Infarct size was also assessed using Masson's trichrome staining. Results : At 24 h post-infarction, CMR-derived infarction together with significant reduction in systolic function and glucose metabolism were already noted in both models. At 21-day CMR, however, reperfused mice showed lower infarct size and more preserved systolic function compared to their non-reperfused counterparts, while no differences in glucose metabolism were reported. Infarct size and systolic function at 1-day CMR and the number of segments with reduced glucose consumption at 1-day PET independently predicted histology-derived infarct size and long-term systolic function. Conclusions : Combined PET/CMR imaging enables non-invasive, sequential evaluation of infarct size, systolic function, and glucose metabolism in experimental myocardial infarction. This multimodality approach is well suited for assessing the efficacy of emerging therapies in preclinical research.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Modulating Effect of Carbohydrate Antigen 125 on the Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure

  • Santas, Enrique
  • Martí-Martínez, Arancha
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Villar, Sandra|||0000-0001-8229-6279
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Palau, Patricia|||0000-0001-5040-0924
  • Llàcer-Iborra, Pau|||0000-0002-0988-0599
  • Miñana, Gema|||0000-0001-8777-2588
  • Rodriguez-Borja, Enrique|||0000-0002-0339-6704
  • Carratala, Arturo|||0000-0003-4513-7214
  • González, Arantxa|||0000-0001-5986-6528
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Sanchis, Juan|||0000-0003-0797-8709
  • Núñez, Julio|||0000-0003-1672-7119
Inflammation and congestion are key pathophysiological processes in heart failure (HF). Our aim was to evaluate the potential modulatory effect of carbohydrate antigen 125 (CA125) on inflammation, assessed by high-sensitivity C-reactive protein (hs-CRP). We analyzed a cohort of 4043 consecutive patients in whom hs-CRP and CA125 levels were measured during a hospitalization for acute HF. Multivariate Cox regression models were applied to assess the association between the biomarkers and all-cause mortality and death/HF rehospitalization at 6 months. In multivariable analysis, a significant interaction between hs-CRP and CA125 was observed for both outcomes (p -value for interaction = 0.036 and <0.001, respectively). hs-CRP was significantly associated with an increased risk of death (HR = 1.27; 95% CI 1.16-1.41; p < 0.001) and death/HF rehospitalization (HR = 1.18; 95% CI 1.09-1.28; p < 0.001) if CA125 > 35 U/mL. In contrast, hs-CRP was not predictive of events when CA125 ≤ 35 U/mL. In conclusion, in patients with acute HF, the association between hs-CRP and clinical outcomes was modulated by CA125 levels. hs-CRP was associated with a higher risk of events only in patients with elevated CA125. These findings support a potential modulatory and amplifying role for CA125 in the inflammatory response in HF.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Role of Antigen Carbohydrate 125 in Modulating Soluble ST2, Prognostic-Related Effects in Acute Heart Failure

  • Martí-Martínez, Arancha
  • Núñez, Julio|||0000-0003-1672-7119
  • López Escribano, Herminio
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Mollar, Anna
  • Peiró, Marta
  • Sanchis, Juan|||0000-0003-0797-8709
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Carratala, Arturo|||0000-0003-4513-7214
  • Miró, Oscar|||0000-0002-7924-9751
  • Llorens Soriano, Pere|||0000-0002-9291-7179
  • Herrero-Puente, Pablo|||0000-0002-5529-5008
Background: Acute heart failure (AHF) is a complex syndrome associated with high mortality and hospital readmissions, characterized by volume overload and inflammation. Soluble ST2 (sST2) and antigen carbohydrate 125 (CA125) are emerging biomarkers that reflect these processes and may interact to influence long-term outcomes in AHF patients. This study aims to examine the prognostic relationship between sST2 and CA125 in predicting mortality and heart failure (HF)-related hospitalizations in patients with decompensated heart failure. Methods: In a cohort of 635 patients with AHF, we investigated whether the prognostic value of sST2 varies according to CA125 levels (≤35 vs. >35 U/mL). The endpoints were: (a) time to all-cause death, and (b) the combination of time to death or new HF admission. Results: This study of EAHFE registry data shows that the association between sST2 and long-term adverse outcomes (mortality and HF hospitalizations) in patients with AHF was differentially influenced by CA125 concentrations (p-value for interactions = 0.031 and 0.029, respectively). Higher sST2 was associated with the risk of death and the combined risk of death/HF readmission when CA125 was >35 U/mL [HR = 1.02 (CI 95%: 1.01-1.04), p = 0.006 and 1.02 (CI 95%: 1.01-1.03); p = 0.013 per increase in 10 ng/mL, respectively], but not when CA125 was ≤35 U/mL. Conclusions: This study highlights the prognostic interaction between sST2 and CA125 in AHF. Elevated sST2 predicts poor outcomes mainly in patients with high CA125 levels (>35 U/mL), suggesting CA125's role in modulating inflammatory activity in HF. Further research is needed.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Local administration of porcine immunomodulatory, chemotactic and angiogenic extracellular vesicles using engineered cardiac scaffolds for myocardial infarction

  • Moron-Font, Miriam
  • Clos-Sansalvador, Marta
  • Calle, Alexandra
  • Morancho Retana, Anna
  • Rosell Novel, Anna
  • Monguió-Tortajada, Marta
  • Prat-Vidal, Cristina
  • Gastelurrutia, Paloma
Ingeniería de tejido cardíaco; Exosomas; Infiltración, Enginyeria de teixits cardíacs; Exosomes; Infiltració, Cardiac tissue engineering; Exosomes; Infiltration, The administration of extracellular vesicles (EV) from mesenchymal stromal cells (MSC) is a promising cell-free nanotherapy for tissue repair after myocardial infarction (MI). However, the optimal EV delivery strategy remains undetermined. Here, we designed a novel MSC-EV delivery, using 3D scaffolds engineered from decellularised cardiac tissue as a cell-free product for cardiac repair. EV from porcine cardiac adipose tissue-derived MSC (cATMSC) were purified by size exclusion chromatography (SEC), functionally analysed and loaded to scaffolds. cATMSC-EV markedly reduced polyclonal proliferation and pro-inflammatory cytokines production (IFNγ, TNFα, IL12p40) of allogeneic PBMC. Moreover, cATMSC-EV recruited outgrowth endothelial cells (OEC) and allogeneic MSC, and promoted angiogenesis. Fluorescently labelled cATMSC-EV were mixed with peptide hydrogel, and were successfully retained in decellularised scaffolds. Then, cATMSC-EV-embedded pericardial scaffolds were administered in vivo over the ischemic myocardium in a pig model of MI. Six days from implantation, the engineered scaffold efficiently integrated into the post-infarcted myocardium. cATMSC-EV were detected within the construct and MI core, and promoted an increase in vascular density and reduction in macrophage and T cell infiltration within the damaged myocardium. The confined administration of multifunctional MSC-EV within an engineered pericardial scaffold ensures local EV dosage and release, and generates a vascularised bioactive niche for cell recruitment, engraftment and modulation of short-term post-ischemic inflammation., This work was supported in part by grants from Fundació la Marató de TV3 (201516-10, 201502-30), the PERIS (SLT002/16/00234) and SGR programmes (2017-SGR-301 REMAR Group, 2017-SGR-1427 and 2017-SGR-483 ICREC Group) from the Generalitat de Catalunya, the Spanish Ministry of Economy and Competitiveness-MICINN (SAF2017-84324-C2-1-R; PID2019-110137RB-I00; PID2019-107145RB-I00), Instituto de Salud Carlos III (PI17/01487, PIC18/00014, ICI19/00039, PI18/00256, PI18/01227, and ICI20/00135), ISCIII-REDinREN (RD16/0009 Feder Funds), Red de Terapia Celular-TerCel (RD16/0011/0006), CIBER Cardiovascular (CB16/11/00403) projects as a part of the Plan Nacional de I + D + I, and it was co-funded by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER), AGAUR (2019PROD00122), Sociedad Española de Cardiología, Societat Catalana de Cardiologia, PCMR[C] and EoI Collaborative Projects on Regenerative Medicine 2019, and Institut Català de Salut (ICS). PG is sponsored by the PERIS (SLT002/16/00209) from the Generalitat de Catalunya. AR is supported by the Miguel Servet program (CPII15/00003) and research grants (PI16/00981) from the Instituto de Salud Carlos III, and co-financed by the European Regional Development Fund. FEB is a researcher from Fundació Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, supported by the Health Department of the Catalan Government (Generalitat de Catalunya).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience

  • Vives Armengol, Joaquim
  • Coll, Ruth
  • Gálvez-Montón, Carolina
  • Prat-Vidal, Cristina
  • Gastelurrutia, Paloma
  • Bayes-Genis, Antoni
Medicament de teràpia avançada; Medicament en investigació; Translacional (regulació), Medicamento de terapia avanzada; Medicamento en investigación; Traslacional (regulación), Advanced therapy medicinal product; Investigational medicinal product; Translational (regulation), A systematic and ordered product development program, in compliance with current quality and regulatory standards, increases the likelihood of yielding a successful advanced therapy medicinal product (ATMP) for clinical use as safe and effective therapy. As this is a novel field, little accurate information is available regarding the steps to be followed, and the information to be produced to support the development and use of an ATMP. Notably, successful clinical translation can be somewhat cumbersome for academic researchers. In this article, we have provided a summary of the available information, supported by our experience in Spain throughout the development of an ATMP for myocardial infarction, from the pre-clinical stage to phase I clinical trial approval., This work was supported by the Spanish Cell Therapy Network (TerCel) [RD16/0011/0006 and RD16/0011/0028]; and CIBER Cardiovascular [CB16/11/00403] projects, as a part of the National R&D&I Plan, and was co-funded by the ISCIII-Sub-Directorate General for Research Assessment and Promotion and the European Regional Development Fund (ERDF); the Government of Catalonia: Agency for Management of University and Research Grants (AGAUR) [2017-SGR-483 and 2017-SGR-719], PERIS Program (Health Department) [SLT002/16/00234 and SLT002/16/00209] and CERCA Program; La Caixa Banking Foundation; grants from the Spanish Ministry of Science, Innovation and Universities (MICINN) [SAF2017-84324-C2-1-R]; Institute of Health Carlos III (ISCIII) [PI18/00256, PIC18/00014, ICI19/00039, and PI19/01788], and cofunded by European Union (ERDF/ESF) - A way to build Europe. This work has also been funded by the Sociedad Española de Cardiología and by the Call for Expression of Interest (EoI) for Collaborative Projects on Regenerative Medicine 2019 of Center for Regenerative Medicine of Barcelona (CMR[B]). The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Intracoronary Administration of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells Improves Myocardial Perfusion But Not Left Ventricle Function, in a Translational Model of Acute Myocardial Infarction

  • Bobi, Joaquim|||0000-0002-9026-5226
  • Solanes, Núria
  • Fernández-Jiménez, Rodrigo
  • Galán-Arriola, Carlos
  • Dantas, A. P.|||0000-0001-8514-4094
  • Fernández-Friera, Leticia
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Rigol-Monzó, Elisabet
  • Agüero, Jaume|||0000-0001-7416-871X
  • Ramírez, José
  • Roqué, Mercè
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Sánchez González, Javier|||0000-0003-1427-3870
  • García-Álvarez, Ana|||0000-0002-1718-2424
  • Sabaté, Manel
  • Rudilla, F..
  • Ibañez, Borja|||0000-0002-5036-254X
  • Rigol, Montserrat
Autologous adipose tissue-derived mesenchymal stem cells (s) therapy is a promising strategy to improve post-myocardial infarction outcomes. In a porcine model of acute myocardial infarction, we studied the long-term effects and the mechanisms involved in allogeneic s administration on myocardial performance. Thirty-eight pigs underwent 50 minutes of coronary occlusion; the study was completed in 33 pigs. After reperfusion, allogeneic s or culture medium (vehicle) were intracoronarily administered. Follow-ups were performed at short (2 days after acute myocardial infarction vehicle-treated, n=10; s-treated, n=9) or long term (60 days after acute myocardial infarction vehicle-treated, n=7; s-treated, n=7). At short term, infarcted myocardium analysis showed reduced apoptosis in the s-treated animals (48.6±6% versus 55.9±5.7% in vehicle; P =0.017); enhancement of the reparative process with up-regulated vascular endothelial growth factor, granulocyte macrophage colony-stimulating factor, and stromal-derived factor-1α gene expression; and increased M2 macrophages (67.2±10% versus 54.7±10.2% in vehicle; P =0.016). In long-term groups, increase in myocardial perfusion at the anterior infarct border was observed both on day-7 and day-60 cardiac magnetic resonance studies in s-treated animals, compared to vehicle (87.9±28.7 versus 57.4±17.7 mL/min per gram at 7 days; P =0.034 and 99±22.6 versus 43.3±14.7 22.6 mL/min per gram at 60 days; P =0.0001, respectively). At day 60, higher vascular density was detected at the border zone in the s-treated animals (118±18 versus 92.4±24.3 vessels/mm 2 in vehicle; P =0.045). Cardiac magnetic resonance-measured left ventricular ejection fraction of left ventricular volumes was not different between groups at any time point. In this porcine acute myocardial infarction model, allogeneic s-based therapy was associated with increased cardioprotective and reparative mechanisms and with better cardiac magnetic resonance-measured perfusion. No effect on left ventricular volumes or ejection fraction was observed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mechanisms of action of sacubitril/valsartan on cardiac remodeling, a systems biology approach

  • Iborra Egea, Oriol|||0000-0002-7280-859X
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Rudilla, F..
  • Perea Gil, Isaac
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Sacubitril/Valsartan, proved superiority over other conventional heart failure management treatments, but its mechanisms of action remains obscure. In this study, we sought to explore the mechanistic details for Sacubitril/Valsartan in heart failure and post-myocardial infarction remodeling, using an in silico, systems biology approach. Myocardial transcriptome obtained in response to myocardial infarction in swine was analyzed to address post-infarction ventricular remodeling. Swine transcriptome hits were mapped to their human equivalents using Reciprocal Best (blast) Hits, Gene Name Correspondence, and InParanoid database. Heart failure remodeling was studied using public data available in gene expression omnibus (accession GSE57345, subseries GSE57338), processed using the GEO2R tool. Using the Therapeutic Performance Mapping System technology, dedicated mathematical models trained to fit a set of molecular criteria, defining both pathologies and including all the information available on Sacubitril/Valsartan, were generated. All relationships incorporated into the biological network were drawn from public resources (including KEGG, REACTOME, INTACT, BIOGRID, and MINT). An artificial neural network analysis revealed that Sacubitril/Valsartan acts synergistically against cardiomyocyte cell death and left ventricular extracellular matrix remodeling via eight principal synergistic nodes. When studying each pathway independently, Valsartan was found to improve cardiac remodeling by inhibiting members of the guanine nucleotide-binding protein family, while Sacubitril attenuated cardiomyocyte cell death, hypertrophy, and impaired myocyte contractility by inhibiting PTEN. The complex molecular mechanisms of action of Sacubitril/Valsartan upon post-myocardial infarction and heart failure cardiac remodeling were delineated using a systems biology approach. Further, this dataset provides pathophysiological rationale for the use of Sacubitril/Valsartan to prevent post-infarct remodeling. The new wonder drug in heart failure management, Sacubitril/Valsartan, rejuvenates the heart by preventing its dilation. Using data from myocardial infarction and heart failure samples, we generated a mathematical model to better understand how Sacubitril/Valsartan modulates pathological heart resize and the combined effect of the drug. Our analysis revealed that Sacubitril/Valsartan mainly acts by blocking both, cell death and the pathological makeover of the outer-membrane of the cardiac cells. These two major processes occur after a heart attack. Most importantly, we discovered a core of 8 proteins that emerge as key players in this process. A better understanding of the mechanism of novel cardiovascular drugs at the most basic level may help decipher future therapies and indications.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Telomere attrition in heart failure, a flow-FISH longitudinal analysis of circulating monocytes

  • Teubel, Iris
  • Elchinova, Elena Georgieva
  • Roura, Santiago|||0000-0003-4063-9661
  • Fernández, Marco A.|||0000-0002-3921-2209
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Moliner, P.|||0000-0002-5511-8597
  • de Antonio Ferrer, Marta|||0000-0002-4319-797X
  • Lupón, Josep|||0000-0002-5601-9611
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Cross-sectional investigations report shorter telomeres in patients with heart failure (HF); however, no studies describe telomere length (TL) trajectory and its relationship with HF progression. Here we aimed to investigate telomere shortening over time and its relationship to outcomes. Our study cohort included 101 ambulatory patients with HF. Blood samples were collected at baseline (n = 101) and at the 1-year follow-up (n = 54). Using flow-FISH analysis of circulating monocytes, we simultaneously measured three monocyte subsets-classical (CD14 ++ CD16 -), intermediate (CD14 ++ CD16 +), and nonclassical (CD14 + CD16 ++)-and their respective TLs based on FITC-labeled PNA probe hybridization. The primary endpoints were all-cause death and the composite of all-cause death or HF-related hospitalization, assessed at 2.3 ± 0.6 years. All statistical analyses were executed by using the SPSS 15.0 software, and included Student's t test and ANOVA with post hoc Scheffe analysis, Pearson or Spearman rho correlation and univariate Cox regression when applicable. We found high correlations between TL values of different monocyte subsets: CD14 ++ CD16 + vs. CD14 ++ CD16 -, R = 0.95, p < 0.001; CD14 ++ CD16 + vs. CD14 + CD16 ++, R = 0.90, p < 0.001; and CD14 ++ CD16 - vs. CD14 + CD16 ++, R = 0.89, p < 0.001. Mean monocyte TL exhibited significant attrition from baseline to the 1-year follow-up (11.1 ± 3.3 vs. 8.3 ± 2.1, p < 0.001). TL did not significantly differ between monocyte subsets at either sampling time-point (all p values.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prognostic value of the Stanniocalcin-2/PAPP-A/IGFBP-4 axis in ST-segment elevation myocardial infarction

  • Cediel, Germán|||0000-0001-9667-7507
  • Rueda, Ferran|||0000-0001-5464-4870
  • Oxvig, Claus
  • Oliveras, Teresa
  • Labata, Carlos|||0000-0002-4505-0787
  • De Diego, Oriol|||0000-0002-8476-7094
  • Ferrer Massot, Marc|||0000-0003-0046-1301
  • Aranda-Nevado, M. Cruz
  • Serra-Gregori, Judith
  • Núñez, Julio|||0000-0003-1672-7119
  • Garcia Garcia, Cosme|||0000-0001-6330-1677
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
The aim of the present study was to evaluate the prognostic value of the Stanniocalcin-2/PAPP-A/IGFBP-4 axis in patients with ST-segment elevation myocardial infarction (STEMI). Observational cohort study performed in 1085 consecutive STEMI patients treated with early reperfusion between February 2011 and August 2014. Stanniocalcin-2, PAPP-A, and IGFBP-4 were measured using state-of-the art immunoassays. The primary outcome was the composite endpoint of all-cause mortality and readmission due to heart failure (HF). Median follow-up was 3.3 years (IQR 1.0-3.7), during which 176 patients (16.2%) presented a composite endpoint. Multivariable cox regression analysis revealed that Stanniocalcin-2 (HR 2.06; 95% CI 1.13-3.75; p = 0.018), IGFBP-4 (HR 1.73; 95% CI 1.14-2.64; p = 0.010), Killip-Kimball class III-IV (HR 1.40; 95% CI 1.13-1.74; p = 0.002), NT-ProBNP (HR 1.21; 95% CI 1.07-1.37; p = 0.002), age (HR 1.06; 95% CI 1.04-1.08; p < 0.001) and left ventricular ejection fraction (HR 0.97; 95% CI 0.95-0.98; p < 0.001) were independent predictors of the composite endpoint. A model containing Stanniocalcin-2 and IGFBP-4 on top of clinical variables significantly improved C-index discrimination (p = 0.036). Stanniocalcin-2 was also identified as independent predictor of all-cause mortality (HR 2.23; 95% CI 1.16-4.29; p = 0.017) and readmission due to HF (HR 3.42; 95% CI 1.22-9.60; p = 0.020). In STEMI patients, Stanniocalcin-2 and IGFBP-4 emerged as independent predictors of all-cause death and readmission due to HF. The Stanniocalcin-2/PAPP-A/IGFBP-4 axis exhibits a significant role in STEMI risk stratification.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mesenchymal stem cells induce expression of cD73 in human monocytes in vitro and in a swine model of myocardial infarction in vivo

  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Rudilla, F..
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
The ectoenzymes CD39 and CD73 regulate the purinergic signaling through the hydrolysis of adenosine triphosphate (ATP)/ADP to AMP and to adenosine (Ado), respectively. This shifts the pro-inflammatory milieu induced by extracellular ATP to the anti- inflammatory regulation by Ado. Mesenchymal stem cells (MSCs) have potent immunomodulatory capabilities, including monocyte modulation toward an anti-inflammatory phenotype aiding tissue repair. In vitro, we observed that human cardiac adipose tissue-derived MSCs (cATMSCs) and umbilical cord MSCs similarly polarize monocytes toward a regulatory M2 phenotype, which maintained the expression of CD39 and induced expression of CD73 in a cell contact dependent fashion, correlating with increased functional activity. In addition, the local treatment with porcine cATMSCs using an engineered bioactive graft promoted the in vivo CD73 expression on host monocytes in a swine model of myocardial infarction. Our results suggest the upregulation of ectonucleotidases on MSC-conditioned monocytes as an effective mechanism to amplify the long-lasting immunomodulatory and healing effects of MSCs delivery.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Determination of HLA-A, -B, -C, -DRB1 and -DQB1 allele and haplotype frequencies in heart failure patients

  • Rudilla, Francesc|||0000-0002-3099-067X
  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Enrich, Emma|||0000-0001-9183-1333
  • Campos, Eva
  • Lupón, Josep|||0000-0002-5601-9611
  • Santiago Vacas, Evelyn|||0000-0001-7511-406X
  • Querol, Sergi|||0000-0002-1105-8633
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Aims: Cell therapy can be used to repair functionally impaired organs and tissues in humans. Although autologous cells have an immunological advantage, it is difficult to obtain high cell numbers for therapy. Well-characterized banks of cells with human leukocyte antigens (HLA) that are representative of a given population are thus needed. The present study investigates the HLA allele and haplotype frequencies in a cohort of heart failure (HF) patients. Methods and results: We carried out the HLA typing and the allele and haplotype frequency analysis in 247 ambulatory HF patients. We determined HLA class I (A, B, and C) and class II (DRB1 and DQB1) using next-generation sequencing technology. The allele frequencies were obtained using Python for Population Genomics (PyPop) software, and HLA haplotypes were estimated using HaploStats. A total of 30 HLA-A, 56 HLA-B, 23 HLA-C, 36 HLA-DRB1, and 15 HLA-DQB1 distinct alleles were identified within the studied cohort. The genotype frequencies of all five HLA loci were in Hardy-Weinberg equilibrium. We detected differences in HLA allele frequencies among patients when the etiological cause of HF was considered. There were a total of 494 five-loci haplotypes, five of which were present six or more times. Moreover, the most common estimated HLA haplotype was HLA-A*01:01, HLA-B*08:01, HLA-C*07:01, HLA-DRB1*03:01, and HLA-DQB1*02:01 (6.07% haplotype frequency per patient). Remarkably, the 11 most frequent haplotypes would cover 31.17% of the patients of the cohort in need of allogeneic cell therapy. Conclusions: Our findings could be useful for improving allogeneic cell administration outcomes without concomitant immunosuppression.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure, a pilot study

  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Núñez, Julio|||0000-0003-1672-7119
  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Januzzi, James L.
  • Ibrahim, Nasrien E.
  • Emdin, Michele
  • VanKimmenade, Roland
  • Pascual-Figal, DA.|||0000-0002-4993-9540
  • Núñez, Eduardo
  • Gommans, Frank
  • Lupón, Josep|||0000-0002-5601-9611
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor developed for the treatment of heart failure with reduced ejection fraction. Its benefits are achieved through the inhibition of neprilysin (NEP) and the specific blockade of the angiotensin receptor AT1. The many peptides metabolized by NEP suggest multifaceted potential consequences of its inhibition. We sought to evaluate the short-term changes in serum endorphin (EP) values and their relation with patients' physical functioning after initiation of sacubitril/valsartan treatment. A total of 105 patients with heart failure with reduced ejection fraction, who were candidates for sacubitril/valsartan treatment, were included in this prospective, observational, multicentre, and international study. In a first visit, and in agreement with current guidelines, treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blocker was replaced by sacubitril/valsartan because of clinical indication by the responsible physician. By protocol, patients were reevaluated at 30 days after the start of sacubitril/valsartan. Serum levels of α- (α-EP), γ-Endorphin (γ-EP), and soluble NEP (sNEP) were measured using enzyme-linked immunoassays. New York Heart Association (NYHA) functional class was used as an indicator of patient's functional status. Baseline median levels of circulating α-EP, γ-EP, and sNEP were 582 (160-772), 101 (37-287), and 222 pg/mL (124-820), respectively. There was not a significant increase in α-EP nor γ-EP serum values after sacubitril/valsartan treatment (P value = 0.194 and 0.102, respectively). There were no significant differences in sNEP values between 30 days and baseline (P value = 0.103). Medians (IQR) of Δα-EP, Δγ-EP, and ΔsNEP between 30 days and baseline were 9.3 (-34 - 44), -3.0 (-46.0 - 18.9), and 0 units (-16.4 - 157.0), respectively. In a pre-post sacubitril/valsartan treatment comparison, there was a significant improvement in NYHA class, with 36 (34.3%) patients experiencing improvement by at least one NYHA class category. Δα-EP and ΔsNEP showed to be significantly associated with NYHA class after 30 days of treatment (P = 0.014 and P < 0.001, respectively). Δα-EP was linear and significantly associated with NYHA class improvement after 30 days of sacubitril/valsartan treatment. These preliminary data suggest that beyond the haemodynamic benefits achieved with sacubitril/valsartan, the altered cleavage of endorphin peptides by NEP inhibition may participate in patients' symptoms improvement.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron, The Myocardial- Trial

  • Núñez, Julio|||0000-0003-1672-7119
  • Miñana, Gema|||0000-0001-8777-2588
  • Cardells, Ingrid
  • Palau, Patricia|||0000-0001-5040-0924
  • Llàcer, Pau
  • Facila Rubio, Lorenzo|||0000-0003-1402-4364
  • Almenar Bonet, Luis|||0000-0002-7710-361X
  • López-Lereu, Maria P.
  • Monmeneu, Jose V.
  • Amiguet, Martina
  • González, Jessika
  • Serrano, Alicia
  • Montagud, Vicente
  • López-Vilella, Raquel
  • Valero, Ernesto
  • García Blas, Sergio
  • Bodi, Vicente|||0000-0001-6425-5828
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Lupón, Josep|||0000-0002-5601-9611
  • Navarro, Jorge
  • Górriz, Jose Luis|||0000-0002-1134-9051
  • Sanchis, Juan|||0000-0003-0797-8709
  • Chorro, Francisco J.
  • Comín-Colet, Josep|||0000-0001-8780-720X
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Intravenous ferric carboxymaltose () improves symptoms, functional capacity, and quality of life in heart failure and iron deficiency. The mechanisms underlying these effects are not fully understood. The aim of this study was to examine changes in myocardial iron content after administration in patients with heart failure and iron deficiency using cardiac magnetic resonance. Fifty-three stable heart failure and iron deficiency patients were randomly assigned 1:1 to receive intravenous or placebo in a multicenter, double-blind study. T2* and T1 mapping cardiac magnetic resonance sequences, noninvasive surrogates of intramyocardial iron, were evaluated before and 7 and 30 days after randomization using linear mixed regression analysis. Results are presented as least-square means with 95% CI. The primary end point was the change in T2* and T1 mapping at 7 and 30 days. Median age was 73 (65-78) years, with N-terminal pro-B-type natriuretic peptide, ferritin, and transferrin saturation medians of 1690 pg/mL (1010-2828), 63 ng/mL (22-114), and 15.7% (11.0-19.2), respectively. Baseline T2* and T1 mapping values did not significantly differ across treatment arms. On day 7, both T2* and T1 mapping (ms) were significantly lower in the arm (36.6 [34.6-38.7] versus 40 [38-42.1], P =0.025; 1061 [1051-1072] versus 1085 [1074-1095], P =0.001, respectively). A similar reduction was found at 30 days for T2* (36.3 [34.1-38.5] versus 41.1 [38.9-43.4], P =0.003), but not for T1 mapping (1075 [1065-1085] versus 1079 [1069-1089], P =0.577). In patients with heart failure and iron deficiency, administration was associated with changes in the T2* and T1 mapping cardiac magnetic resonance sequences, indicative of myocardial iron repletion. : . Unique identifier: 03398681.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure

  • Núñez, Julio|||0000-0003-1672-7119
  • Núñez, Eduardo
  • Barallat, Jaume|||0000-0003-3493-5958
  • Bodi, Vicente|||0000-0001-6425-5828
  • Miñana, Gema|||0000-0001-8777-2588
  • Pastor, M. Cruz
  • Sanchis, Juan|||0000-0003-0797-8709
  • Lupón, Josep|||0000-0002-5601-9611
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Our aim was to evaluate the association between the soluble form of neprilysin () levels and long-term all-cause, cardiovascular, and acute heart failure () recurrent admissions in an ambulatory cohort of patients with heart failure. has emerged as a new biomarker with promising implications for prognosis and therapy in patients with heart failure. Reducing the recurrent admission rate of heart failure patients has become an important target of public health planning strategies. We measured levels in 1021 consecutive ambulatory heart failure patients. End points were the number of all-cause, cardiovascular, and hospitalizations during follow-up. We used covariate-adjusted incidence rate ratios to identify associations. At a median follow-up of 3.4 years (interquartile range: 1.8-5.7), 391 (38.3%) patients died, 477 (46.7%) patients had 1901 all-cause admissions, 324 (31.7%) patients had 770 cardiovascular admissions, and 218 (21.4%) patients had 488 admissions. The medians for and amino-terminal pro-brain natriuretic peptide were 0.64 ng/mL (interquartile range: 0.39-1.22) and 1248 pg/mL (interquartile range: 538-2825), respectively. In a multivariate setting, the adjusted incidence rate ratios for the top (>1.22 ng/mL) versus the bottom (≤0.39 ng/mL) quartiles of were 1.37 (95% confidence interval: 1.03-1.82), P =0.032; 1.51 (95% confidence interval: 1.10-2.06), P =0.010; and 1.51 (95% confidence interval: 1.05-2.16), P =0.026 for all-cause, cardiovascular, and admissions, respectively. Elevated levels predicted an increased risk of recurrent all-cause, cardiovascular, and admissions in ambulatory patients with heart failure.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product, A Spanish Experience

  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
  • Coll-Bonet, Ruth|||0000-0003-0174-379X
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
A systematic and ordered product development program, in compliance with current quality and regulatory standards, increases the likelihood of yielding a successful advanced therapy medicinal product (ATMP) for clinical use as safe and effective therapy. As this is a novel field, little accurate information is available regarding the steps to be followed, and the information to be produced to support the development and use of an ATMP. Notably, successful clinical translation can be somewhat cumbersome for academic researchers. In this article, we have provided a summary of the available information, supported by our experience in Spain throughout the development of an ATMP for myocardial infarction, from the pre-clinical stage to phase I clinical trial approval.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Local administration of porcine immunomodulatory, chemotactic and angiogenic extracellular vesicles using engineered cardiac scaffolds for myocardial infarction

  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Font-Morón, Miriam|||0000-0002-4714-252X
  • Clos Sansalvador, Marta|||0000-0001-8522-7818
  • Calle Arias, Alexandra|||0000-0003-3903-5019
  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Cserkóová, Adriana
  • Morancho, Anna|||0000-0001-9059-3206
  • Ramírez de Paz, Miguel Ángel|||0000-0002-5868-2134
  • Rosell Novel, Anna|||0000-0003-1082-3599
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Rudilla, F..
The administration of extracellular vesicles (EV) from mesenchymal stromal cells (MSC) is a promising cell-free nanotherapy for tissue repair after myocardial infarction (MI). However, the optimal EV delivery strategy remains undetermined. Here, we designed a novel MSC-EV delivery, using 3D scaffolds engineered from decellularised cardiac tissue as a cell-free product for cardiac repair. EV from porcine cardiac adipose tissue-derived MSC (cATMSC) were purified by size exclusion chromatography (SEC), functionally analysed and loaded to scaffolds. cATMSC-EV markedly reduced polyclonal proliferation and pro-inflammatory cytokines production (IFNγ, TNFα, IL12p40) of allogeneic PBMC. Moreover, cATMSC-EV recruited outgrowth endothelial cells (OEC) and allogeneic MSC, and promoted angiogenesis. Fluorescently labelled cATMSC-EV were mixed with peptide hydrogel, and were successfully retained in decellularised scaffolds. Then, cATMSC-EV-embedded pericardial scaffolds were administered in vivo over the ischemic myocardium in a pig model of MI. Six days from implantation, the engineered scaffold efficiently integrated into the post-infarcted myocardium. cATMSC-EV were detected within the construct and MI core, and promoted an increase in vascular density and reduction in macrophage and T cell infiltration within the damaged myocardium. The confined administration of multifunctional MSC-EV within an engineered pericardial scaffold ensures local EV dosage and release, and generates a vascularised bioactive niche for cell recruitment, engraftment and modulation of short-term post-ischemic inflammation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure

  • Bertomeu-González, Vicente|||0000-0001-5309-0562
  • Facila Rubio, Lorenzo|||0000-0003-1402-4364
  • Palau, Patricia|||0000-0001-5040-0924
  • Miñana, Gema|||0000-0001-8777-2588
  • Núñez, Gonzalo
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Santas, Enrique
  • Núñez, Eduardo
  • Bodi, Vicente|||0000-0001-6425-5828
  • Chorro, Francisco J.
  • Cordero, Alberto|||0000-0003-0000-7109
  • Sanchis, Juan|||0000-0003-0797-8709
  • Lupón, Josep|||0000-0002-5601-9611
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Núñez, Julio|||0000-0003-1672-7119
Type 2 diabetes mellitus (T2DM) is common in patients with heart failure (HF) and is related with worse outcomes. Insulin treatment is associated with sodium and water retention, weight gain, and hypoglycaemia-all pathophysiological mechanisms related to HF decompensation. This study aimed to evaluate the association between insulin treatment and the risk of 1 year readmission for HF in patients discharged for acute HF. We prospectively included 2895 consecutive patients discharged after an episode of acute HF in a single tertiary hospital. Multivariable Cox regression, adapted for competing events, was used to assess the association between insulin treatment and 1 year readmission for HF in patients discharged after acute HF. Participants' mean age was 73.4 ± 11.2 years, 50.8% were women, 44.7% had T2DM [including 527 (18.2%) on insulin therapy], and 52.7% had preserved ejection fraction. At 1 year follow-up, 518 (17.9%) patients had died and 693 (23.9%) were readmitted for HF. The crude risk of readmission for HF was higher in patients on insulin, with no differences in 1 year mortality. After multivariable adjustment, patients on insulin were at significantly higher risk of 1 year readmission for HF than patients with diabetes who were not on insulin (hazard ratio 1.28; 95% confidence interval 1.04-1.59, P = 0.022) and patients without diabetes (hazard ratio 1.26; 95% confidence interval 1.02-1.55, P = 0.035). Following acute HF, patients with T2DM on insulin therapy are at increased risk of readmission for HF. Further studies unravelling the mechanisms behind this association are warranted.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes

  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Morillas, Herminio
  • Bravo, Rafael
  • Vidal, Verónica
  • Núñez, Eduardo
  • Santas, Enrique
  • Miñana, Gema|||0000-0001-8777-2588
  • Sanchis, Juan|||0000-0003-0797-8709
  • Facila Rubio, Lorenzo|||0000-0003-1402-4364
  • Torres, Francisco
  • Górriz, Jose Luis|||0000-0002-1134-9051
  • Valle, Alfonso
  • Núñez, Julio|||0000-0003-1672-7119
The aim of this study was to evaluate the safety profile in terms of changes in renal function after co-treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). This multicentre observational analysis included 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23). The primary endpoint was estimated glomerular filtration rate (eGFR) dynamics across treatment groups. A binary characterization of worsening renal function (WRF)/improved renal function (IRF) was included in the primary endpoint. WRF and IRF were defined as an increase/decrease in serum creatinine ≥ 0.3 mg/dL or GFR ≥ 20%. Changes in quantitative variables were evaluated using joint modelling of survival and longitudinal data (JM). Rates and their treatment differences were determined by Poisson regression. The mean left ventricle ejection fraction and eGFR were 32 ± 6% and 70 ± 28 mL/min/1.73 m 2, respectively. At a median follow-up of 1.01 years (inter-quartile range 0.71-1.50), 377 outpatient visits were recorded. Although there were differences in GFR trajectories over time within each treatment, they did not achieve statistical significance (omnibus P = 0.154). However, when these differences were contrasted among groups, there was a significant decrease in GFR in Group A as compared with Group B (P = 0.002). The contrast between Groups C and B was not significant (P = 0.430). These differences were also reflected when the rates for WRF and IRF were contrasted among treatments. The co-administration of sacubitril/valsartan and empagliflozin in patients with HFrEF and concomitant T2D appears to be safe in terms of renal function.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Persistent chest pain after recovery of COVID-19, microvascular disease-related angina?

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction

  • Miñana, Gema|||0000-0001-8777-2588
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Palau, Patricia|||0000-0001-5040-0924
  • Llàcer, Pau
  • Núñez, Eduardo
  • Santas, Enrique
  • Valero, Ernesto
  • Lorenzo, Miguel|||0000-0001-9182-4459
  • Núñez, Gonzalo
  • Bodi, Vicente|||0000-0001-6425-5828
  • Heredia, Raquel
  • Sanchis, Juan|||0000-0003-0797-8709
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Chorro, Francisco J.
  • Núñez, Julio|||0000-0003-1672-7119
We aimed to assess the association between CA125 and the long-term risk of total acute heart failure (AHF) admissions in patients with an index hospitalization with AHF and preserved ejection fraction (HFpEF). We prospectively included 2369 patients between 2008 and 2019 in three centers. CA125 and NT-proBNP were measured during early hospitalization and evaluated as continuous and categorized in quartiles (Q). Negative binomial regressions were used to assess the association with the risk of recurrent AHF admission. The mean age of the sample patients was 76.7 ± 9.5 years and 1443 (60.9%) were women. Median values of CA125 and NT-proBNP were 38.3 (19.0-90.0) U/mL, and 2924 (1590-5447) pg/mL, respectively. During a median follow-up of 2.2 (0.8-4.6) years, 1200 (50.6%) patients died, and 2084 AHF admissions occurred in 1029 (43.4%) patients. After a multivariate adjustment, CA125, but not NT-proBNP, was positively and non-linearly associated with the risk of cumulative AHF-readmission (p < 0.001). Compared to Q1, patients belonging to Q2, Q3, and Q4 showed a stepwise risk increase (IRR = 1.29, 95% CI 1.08-1.55, p = 0.006; IRR = 1.35, 95% CI 1.12-1.63, p = 0.002; and IRR = 1.62, 95% CI 01.34-1.96, p < 0.001, respectively). In conclusion, CA125 predicted the risk of long-term AHF-readmission burden in patients with HFpEF and a recent admission for AHF.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Particle size and cholesterol content of circulating HDL correlate with cardiovascular death in chronic heart failure

  • Teis, Albert|||0000-0002-4820-0736
  • Cediel, Germán|||0000-0001-9667-7507
  • Amigó, Núria|||0000-0002-0116-9145
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Aranyó, Júlia
  • Andrés-Cordón, Joan Francesc|||0000-0003-4264-4499
  • Puig Jové, Carlos|||0000-0001-9466-2627
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Gual-Capllonch, Francisco
  • Ferrer-Sistach, Elena|||0000-0002-1795-2193
  • Vallejo Camazón, Núria|||0000-0001-6644-6767
  • Juncà Puig, Gladys|||0000-0002-4421-5658
  • López Ayerbe, Jorge|||0009-0008-8495-0877
  • de Antonio Ferrer, Marta|||0000-0002-4319-797X
  • Domingo, Mar|||0000-0002-2935-1272
  • Santiago Vacas, Evelyn|||0000-0001-7511-406X
  • Codina, Pau|||0000-0002-2469-5711
  • Mauricio, Didac|||0000-0002-2868-0250
  • Lupón, Josep|||0000-0002-5601-9611
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Evidence regarding any association of HDL-particle (HDL-P) derangements and HDL-cholesterol content with cardiovascular (CV) death in chronic heart failure (HF) is lacking. To investigate the prognostic value of HDL-P size (HDL-Sz) and the number of cholesterol molecules per HDL-P for CV death in HF patients. Outpatient chronic HF patients were enrolled. Baseline HDL-P number, subfractions and HDL-Sz were measured using 1H-NMR spectroscopy. The HDL-C/P ratio was calculated as HDL-cholesterol over HDL-P. Endpoint was CV death, with non-CV death as the competing event. 422 patients were included and followed-up during a median of 4.1 (0-8) years. CV death occurred in 120 (30.5%) patients. Mean HDL-Sz was higher in CV dead as compared with survivors (8.39 nm vs. 8.31 nm, p < 0.001). This change in size was due to a reduction in the percentage of small HDL-P (54.6% vs. 60% for CV-death vs. alive; p < 0.001). HDL-C/P ratio was higher in the CV-death group (51.0 vs. 48.3, p < 0.001). HDL-Sz and HDL-C/P ratio were significantly associated with CV death after multivariable regression analysis (HR 1.22 [95% CI 1.01-1.47], p = 0.041 and HR 1.04 [95% CI 1.01-1.07], p = 0.008 respectively). HDL-Sz and HDL-C/P ratio are independent predictors of CV death in chronic HF patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction, a pilot study

  • Miñana, Gema|||0000-0001-8777-2588
  • Núñez, Julio|||0000-0003-1672-7119
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Ríos-Navarro, César
  • Núñez, Eduardo
  • Chorro, Francisco J.
  • López-Lereu, Maria Pilar
  • Monmeneu, Jose Vicente
  • Lupón, Josep|||0000-0002-5601-9611
  • Sanchis, Juan|||0000-0003-0797-8709
  • Bodi, Vicente|||0000-0001-6425-5828
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for reducing plasma low-density lipoprotein cholesterol. Beyond lipid control, recent findings suggest a deleterious effect of this protein in the pathogenesis of postmyocardial infarction left ventricle remodelling and heart failure-related complications. The aim of this study was to assess the relationship between circulating PCSK9 and 6 month cardiac magnetic resonance imaging-derived left ventricular ejection fraction (LVEF) after a first ST-segment elevation myocardial infarction (STEMI). We prospectively evaluated 40 patients with a first STEMI, LVEF < 50% and treated with primary percutaneous coronary intervention in which PCSK9 was measured 24 h postreperfusion. All patients underwent cardiac magnetic resonance imaging 1 week and 6 months after STEMI. Baseline characteristics were compared across median values of PCSK9. The association between PCSK9 levels and LVEF at 6 months was evaluated by analysis of covariance. The mean age of the sample was 60 ± 12 years and 33 (82.5%) were male patients. The infarct location was anterior in 27 patients (67.5%), and 9 patients (22.5%) were Killip class ≥ II. The mean 1 week and 6 month LVEF were 41 ± 7% and 48 ± 10%, respectively. The mean PCSK9 was 1.93 ± 0.38 U/mL. Testing the association between serum PCSK9 and 6 month LVEF with analysis of covariance revealed an inverse relationship (r = -0.35, P = 0.028). After multivariate adjustment, circulating PCSK9 remained significant and inversely associated with 6 month LVEF (P = 0.002). In patients with a first STEMI with reduced ejection fraction at index admission and treated with primary percutaneous coronary intervention, circulating PCSK9 was associated with lower LVEF at 6 months.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction

  • Santas, Enrique
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Chorro, Francisco J
  • Palau, Patricia|||0000-0001-5040-0924
  • Miñana, Gema|||0000-0001-8777-2588
  • Heredia, Raquel
  • Amiguet, Martina
  • Merenciano, Héctor|||0000-0002-1734-0381
  • Sanchis, Juan|||0000-0003-0797-8709
  • Lupón, Josep|||0000-0002-5601-9611
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Núñez, Julio|||0000-0003-1672-7119
Right ventricular dysfunction (RVD) parameters are increasingly important features in heart failure with preserved ejection fraction (HFpEF). We sought to evaluate the prognostic impact of a progressive RVD staging system by combining the tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery systolic pressure (TAPSE/PASP) ratio with functional tricuspid regurgitation (TR) severity. We prospectively included 1355 consecutive HFpEF patients discharged for acute heart failure (HF). Of them, in 471 (34.7%) patients, PASP could not be accurately measured, leaving the final sample size to be 884 patients. Patients were categorized as Stage 1: TAPSE/PASP ≥ 0.36 without significant TR; stage 2: TAPSE/PASP ≥ 0.36 with significant TR; stage 3: TAPSE/PASP < 0.36 without significant TR; and stage 4: TAPSE/PASP < 0.36 with significant TR. By the 1 year follow-up, 207 (23.4%) patients had died. We found a significant and graded association between RVD stages and mortality rates (15.8%, 25%, 31.2%, and 45.4% from stage 1 to stage 4, respectively; log-rank test, p < 0.001). After multivariable adjustment, and compared to stage 1, stages 3 and 4 were independently associated with mortality risk (HR: 1.8219; 95% CI 1.308-2.538; p < 0.001 and HR = 2.2632; 95% CI 1.540-3.325; p < 0.001, respectively). A RVD staging system, integrating TAPSE/PASP and TR, provides a comprehensive and widely available tool for risk stratification in HFpEF.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Potential of Extracellular Vesicle-Associated TSG-6 from Adipose Mesenchymal Stromal Cells in Traumatic Brain Injury

  • Roura, Santiago|||0000-0003-4063-9661
  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Munizaga-Larroudé, Micaela
  • Clos Sansalvador, Marta|||0000-0001-8522-7818
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Rosell Novel, Anna|||0000-0003-1082-3599
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
Multipotent mesenchymal stromal cells (MSC) represent a promising strategy for a variety of medical applications. Although only a limited number of MSC engraft and survive after in vivo cellular infusion, MSC have shown beneficial effects on immunomodulation and tissue repair. This indicates that the contribution of MSC exists in paracrine signaling, rather than a cell-contact effect of MSC. In this review, we focus on current knowledge about tumor necrosis factor (TNF)-stimulated gene-6 (TSG-6) and mechanisms based on extracellular vesicles (EV) that govern long-lasting immunosuppressive and regenerative activity of MSC. In this context, in particular, we discuss the very robust set of findings by Jha and colleagues, and the opportunity to potentially extend their research focus on EV isolated in concentrated conditioned media (CCM) from adipose tissue derived MSC (ASC). Particularly, the authors showed that ASC-CCM mitigated visual deficits after mild traumatic brain injury in mice. TSG-6 knockdown ASC were, then, used to generate TSG-6-depleted CCM that were not able to replicate the alleviation of abnormalities in injured animals. In light of the presented results, we envision that the infusion of much distilled ASC-CCM could enhance the alleviation of visual abnormalities. In terms of EV research, the advantages of using size-exclusion chromatography are also highlighted because of the enrichment of purer and well-defined EV preparations. Taken together, this could further delineate and boost the benefit of using MSC-based regenerative therapies in the context of forthcoming clinical research testing in diseases that disrupt immune system homeostasis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma microRNA Profiling Reveals Novel Biomarkers of Epicardial Adipose Tissue, A Multidetector Computed Tomography Study

  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Viladés Medel, David|||0000-0002-3638-9703
  • Martínez-Camblor, Pablo|||0000-0001-7845-3905
  • Vea Badenes, Angela|||0000-0001-7856-6635
  • Ferrero-Gregori, Andreu|||0000-0001-6492-2416
  • Nasarre, Laura
  • Bornachea, Olga
  • Sánchez Vega, Jesús|||0000-0001-7250-8362
  • Leta, Rubén|||0000-0003-4691-381X
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Benitez, Sonia|||0000-0003-3565-0743
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Carreras Costa, Francesc|||0000-0002-1944-0562
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Epicardial adipose tissue (EAT) constitutes a novel parameter for cardiometabolic risk assessment and a target for therapy. Here, we evaluated for the first time the plasma microRNA (miRNA) profile as a source of biomarkers for epicardial fat volume (EFV). miRNAs were profiled in plasma samples from 180 patients whose EFV was quantified using multidetector computed tomography. In the screening study, 54 deregulated miRNAs were identified in patients with high EFV levels (highest tertile) compared with matched patients with low EFV levels (lowest tertile). After filtering, 12 miRNAs were selected for subsequent validation. In the validation study, miR-15b-3p, miR-22-3p, miR-148a-3p miR-148b-3p and miR-590-5p were directly associated with EFV, even after adjustment for confounding factors (p value < 0.05 for all models). The addition of miRNA combinations to a model based on clinical variables improved the discrimination (area under the receiver-operating-characteristic curve (AUC) from 0.721 to 0.787). miRNAs correctly reclassified a significant proportion of patients with an integrated discrimination improvement (IDI) index of 0.101 and a net reclassification improvement (NRI) index of 0.650. Decision tree models used miRNA combinations to improve their classification accuracy. These results were reproduced using two proposed clinical cutoffs for epicardial fat burden. Internal validation corroborated the robustness of the models. In conclusion, plasma miRNAs constitute novel biomarkers of epicardial fat burden.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic Biomarkers in Cardiovascular Diseases

  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Cardiovascular diseases are the number one cause of death worldwide and greatly impact quality of life and medical costs. Enormous effort has been made in research to obtain new tools for efficient and quick diagnosis and predicting the prognosis of these diseases. Discoveries of epigenetic mechanisms have related several pathologies, including cardiovascular diseases, to epigenetic dysregulation. This has implications on disease progression and is the basis for new preventive strategies. Advances in methodology and big data analysis have identified novel mechanisms and targets involved in numerous diseases, allowing more individualized epigenetic maps for personalized diagnosis and treatment. This paves the way for what is called pharmacoepigenetics, which predicts the drug response and develops a tailored therapy based on differences in the epigenetic basis of each patient. Similarly, epigenetic biomarkers have emerged as a promising instrument for the consistent diagnosis and prognosis of cardiovascular diseases. Their good accessibility and feasible methods of detection make them suitable for use in clinical practice. However, multicenter studies with a large sample population are required to determine with certainty which epigenetic biomarkers are reliable for clinical routine. Therefore, this review focuses on current discoveries regarding epigenetic biomarkers and its controversy aiming to improve the diagnosis, prognosis, and therapy in cardiovascular patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Head-to-head comparison of two engineered cardiac grafts for myocardial repair, From scaffold characterization to pre-clinical testing

  • Perea Gil, Isaac
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Jorba, Ignasi
  • Segú-Vergés, Cristina|||0000-0002-8215-872X
  • Roura, Santiago|||0000-0003-4063-9661
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Iborra Egea, Oriol|||0000-0002-7280-859X
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Fernández, Marco A.|||0000-0002-3921-2209
  • Farré, Ramon|||0000-0002-9084-7824
  • Navajas, Daniel|||0000-0001-7150-9363
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Cardiac tissue engineering, which combines cells and supportive scaffolds, is an emerging treatment for restoring cardiac function after myocardial infarction (MI), although, the optimal construct remains a challenge. We developed two engineered cardiac grafts, based on decellularized scaffolds from myocardial and pericardial tissues and repopulated them with adipose tissue mesenchymal stem cells (ATMSCs). The structure, macromechanical and micromechanical scaffold properties were preserved upon the decellularization and recellularization processes, except for recellularized myocardium micromechanics that was ∼2-fold stiffer than native tissue and decellularized scaffolds. Proteome characterization of the two acellular matrices showed enrichment of matrisome proteins and major cardiac extracellular matrix components, considerably higher for the recellularized pericardium. Moreover, the pericardial scaffold demonstrated better cell penetrance and retention, as well as a bigger pore size. Both engineered cardiac grafts were further evaluated in pre-clinical MI swine models. Forty days after graft implantation, swine treated with the engineered cardiac grafts showed significant ventricular function recovery. Irrespective of the scaffold origin or cell recolonization, all scaffolds integrated with the underlying myocardium and showed signs of neovascularization and nerve sprouting. Collectively, engineered cardiac grafts -with pericardial or myocardial scaffolds- were effective in restoring cardiac function post-MI, and pericardial scaffolds showed better structural integrity and recolonization capability.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

  • Pacho Pacho, Cristina
  • Domingo, Mar|||0000-0002-2935-1272
  • Núñez Aragón, Raquel
  • Lupón, Josep|||0000-0002-5601-9611
  • Núñez, Julio|||0000-0003-1672-7119
  • Barallat, Jaume|||0000-0003-3493-5958
  • Moliner, P.|||0000-0002-5511-8597
  • de Antonio Ferrer, Marta|||0000-0002-4319-797X
  • Santesmases Ejarque, Javier|||0000-0002-1226-1617
  • Cediel, Germán|||0000-0001-9667-7507
  • Roura, Santiago|||0000-0003-4063-9661
  • Pastor, M. Cruz
  • Tor Aguilera, Jordi|||0000-0002-5355-9110
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Heart failure (HF) is associated with a high rate of readmissions within 30 days post-discharge and in the following year, especially in frail elderly patients. Biomarker data are scarce in this high-risk population. This study assessed the value of early post-discharge circulating levels of ST2, NT-proBNP, CA125, and hs-TnI for predicting 30-day and 1-year outcomes in comorbid frail elderly patients with HF with mainly preserved ejection fraction (HFpEF). Blood samples were obtained at the first visit shortly after discharge (4.9 ± 2 days). The primary endpoint was the composite of all-cause mortality or HF-related rehospitalization at 30 days and at 1 year. All-cause mortality alone at one year was also a major endpoint. HF-related rehospitalizations alone were secondary end-points. From February 2014 to November 2016, 522 consecutive patients attending the STOP-HF Clinic were included (57.1% women, age 82 ± 8.7 years, mean Barthel index 70 ± 25, mean Charlson comorbidity index 5.6 ± 2.2). The composite endpoint occurred in 8.6% patients at 30 days and in 38.5% at 1 year. In multivariable analysis, ST2 [hazard ratio (HR) 1.53; 95% CI 1.19-1.97; p = 0.001] was the only predictive biomarker at 30 days; at 1 year, both ST2 (HR 1.34; 95% CI 1.15-1.56; p < 0.001) and NT-proBNP (HR 1.19; 95% CI 1.02-1.40; p = 0.03) remained significant. The addition of ST2 and NT-proBNP into a clinical predictive model increased the AUC from 0.70 to 0.75 at 30 days (p = 0.02) and from 0.71 to 0.74 at 1 year (p < 0.05). For all-cause death at 1 year, ST2 (HR 1.50; 95% CI 1.26-1.80; p < 0.001), and CA125 (HR 1.41; 95% CI 1.21-1.63; p < 0.001) remained independent predictors in multivariable analysis. The addition of ST2 and CA125 into a clinical predictive model increased the AUC from 0.74 to 0.78 (p = 0.03). For HF-related hospitalizations, ST2 was the only predictive biomarker in multivariable analyses, both at 30 days and at 1 year. In a comorbid frail elderly population with HFpEF, ST2 outperformed NT-proBNP for predicting the risk of all-cause mortality or HF-related rehospitalization. ST2, a surrogate marker of inflammation and fibrosis, may be a better predictive marker in high-risk HFpEF.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Circulating monocyte subsets and heart failure prognosis

  • Elchinova, Elena Georgieva
  • Teubel, Iris
  • Roura, Santiago|||0000-0003-4063-9661
  • Fernández, Marco A.|||0000-0002-3921-2209
  • Lupón, Josep|||0000-0002-5601-9611
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • de Antonio Ferrer, Marta|||0000-0002-4319-797X
  • Moliner, P.|||0000-0002-5511-8597
  • Domingo, Mar|||0000-0002-2935-1272
  • Zamora, Elisabet|||0000-0001-5317-7481
  • Núñez, Julio|||0000-0003-1672-7119
  • Cediel, Germán|||0000-0001-9667-7507
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Monocytes are a heterogeneous population of effector cells with key roles in tissue integrity restoration and maintenance. Here, we explore the association of monocyte subsets and prognosis in patients with ambulatory heart failure (HF). Monocyte subsets were classified as classical (CD14 ++ /CD16 -), intermediate (CD14 ++ /CD16 +), or non-classical (CD14 + /CD16 ++). Percentage distribution and absolute cell count were assessed in each subset, and multivariable Cox regression analyses were performed with all-cause death, HF-related hospitalization, and the composite end-point of both as dependent variables. 400 patients were consecutively included (72.8% male, age 69.4±12.2 years, 45.5% from ischemic aetiology, left ventricle ejection fraction (LVEF) 41.6% ±14.5, New York Heart Association (NYHA) class II 62.8% and III 30.8%). During a mean follow-up of 2.6±0.9 years, 107 patients died, 99 had a HF-related hospitalization and 160 suffered the composite end-point of all-cause death or HF-related hospitalization. Monocyte subsets assessed in percentages were not independently associated to any of the end-points. When considering number of cells/μL, intermediate subset was independently associated with an increase of all-cause death (HR 1.25 [95% CI 1,02-1.52], p = 0.03), and the composite end-point HR 1.20 [95% CI 1,03-1.40], p = 0.02). The presented findings show that absolute cell count of monocyte subsets was preferred over monocyte percentage for prognosis stratification for outpatients with HF. The intermediate monocyte subset provides information on increased risk of all-cause death and the composite end-point.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Ex vivo assessment and in vivo validation of non-invasive stent monitoring techniques based on microwave spectrometry

  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Arauz-Garofalo, Gianluca|||0000-0001-5166-6054
  • Rodriguez-Leor, Oriol|||0000-0003-2657-5657
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Amorós García de Valdecasas, Susana
  • Gerez-Britos, Flavio David
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • O'Callaghan, Juan Manuel|||0000-0002-2740-0202
  • Macià, Ferran|||0000-0001-5972-4810
  • Tejada, Javier|||0000-0001-9246-5566
Some conditions are well known to be directly associated with stent failure, including in-stent re-occlusion and stent fracture. Currently, identification of these high-risk conditions requires invasive and complex procedures. This study aims to assess microwave spectrometry (MWS) for monitoring stents non-invasively. Preliminary ex vivo data are presented to move to in vivo validation. Fifteen mice were assigned to receive subcutaneous stent implantations (n = 10) or sham operations (n = 5). MWS measurements were carried out at 0, 2, 4, 7, 14, 22, and 29 days of follow-up. Additionally, 5 stented animals were summited to micro-CT analyses at the same time points. At 29 days, 3 animals were included into a stent fracture subgroup and underwent a last MWS and micro-CT analysis. MWS was able to identify stent position and in-stent stenosis over time, also discerning significant differences from baseline measures (P < 0.001). Moreover, MWS identified fractured vs. non-fractured stents in vivo. Taken together, MWS emerges as a non-invasive, non-ionizing alternative for stent monitoring. MWS analysis clearly distinguished between in-stent stenosis and stent fracture phenomena.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of Frailty on Mortality and Hospitalization in Chronic Heart Failure, A Systematic Review and Meta-Analysis

  • Yang, Xiaobo
  • Lupón, Josep|||0000-0002-5601-9611
  • Vidán, Maria T.
  • Ferguson, Caleb
  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Newton, Phillip J.
  • Macdonald, Peter S.
  • Bueno, Héctor|||0000-0003-0277-7596
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Woo, Jean
  • Fung, Erik|||0000-0002-8209-9467
Background: Although frailty has been associated with increased risks for hospitalization and mortality in chronic heart failure, the precise average effect remains uncertain. We performed a systematic review and meta-analysis to summarize the hazards for mortality and incident hospitalization in patients with heart failure and frailty compared with those without frailty and explored the heterogeneity underlying the effect size estimates. Methods and Results: MEDLINE, EMBASE, and Cochrane databases were queried for articles published between January 1966 and March 2018. Predefined selection criteria were used. Hazard ratios () were pooled for meta-analyses, and where odds ratios were used previously, original data were recalculated for . Overlapping data were consolidated, and only unique data points were used. Study quality and bias were assessed. Eight studies were included for mortality (2645 patients), and 6 studies were included for incident hospitalization (2541 patients) during a median follow-up of 1.82 and 1.12 years, respectively. Frailty was significantly associated with an increased hazard for mortality (, 1.54; 95% confidence interval, 1.34-1.75; P <0.001) and incident hospitalization (, 1.56; 95% confidence interval, 1.36-1.78; P <0.001) in chronic heart failure. The Fried phenotype estimated a 16.9% larger effect size than the combined Fried/non-Fried frailty assessment for the end point of mortality (, 1.80; 95% confidence interval, 1.41-2.28; P <0.001), but not for hospitalization (, 1.57; 95% confidence interval, 1.30-1.89; P <0.001). Study heterogeneity was found to be low (I 2 =0%), and high quality of studies was verified by the Newcastle-Ottawa scale. Conclusions: Overall, the presence of frailty in chronic heart failure is associated with an increased hazard for death and hospitalization by ≈1.5-fold.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • van der Meer, Rutger W.
  • Rijzewijk, Luuk J.
  • Smit, Johannes W. A.
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Nasarre, Laura
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Lamb, Hildo J.
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Using in vitro, in vivo and patient-based approaches, we investigated the potential of circulating microRNAs (miRNAs) as surrogate biomarkers of myocardial steatosis, a hallmark of diabetic cardiomyopathy. We analysed the cardiomyocyte-enriched miRNA signature in serum from patients with well-controlled type 2 diabetes and with verified absence of structural heart disease or inducible ischemia, and control volunteers of the same age range and BMI (N = 86), in serum from a high-fat diet-fed murine model, and in exosomes from lipid-loaded HL-1 cardiomyocytes. Circulating miR-1 and miR-133a levels were robustly associated with myocardial steatosis in type 2 diabetes patients, independently of confounding factors in both linear and logistic regression analyses (P < 0.050 for all models). Similar to myocardial steatosis, miR-133a levels were increased in type 2 diabetes patients as compared with healthy subjects (P < 0.050). Circulating miR-1 and miR-133a levels were significantly elevated in high-fat diet-fed mice (P < 0.050), which showed higher myocardial steatosis, as compared with control animals. miR-1 and miR-133a levels were higher in exosomes released from lipid-loaded HL-1 cardiomyocytes (P < 0.050). Circulating miR-1 and miR-133a are independent predictors of myocardial steatosis. Our results highlight the value of circulating miRNAs as diagnostic tools for subclinical diabetic cardiomyopathy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mesenchymal stem cells for cardiac repair, are the actors ready for the clinical scenario?

  • Roura, Santiago|||0000-0003-4063-9661
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Mirabel, Clémentine
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
For years, sufficient progress has been made in treating heart failure following myocardial infarction; however, the social and economic burdens and the costs to world health systems remain high. Moreover, treatment advances have not resolved the underlying problem of functional heart tissue loss. In this field of research, for years we have actively explored innovative biotherapies for cardiac repair. Here, we present a general, critical overview of our experience in using mesenchymal stem cells, derived from cardiac adipose tissue and umbilical cord blood, in a variety of cell therapy and tissue engineering approaches. We also include the latest advances and future challenges, including good manufacturing practice and regulatory issues. Finally, we evaluate whether recent approaches hold potential for reliable translation to clinical trials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prognostic Value of New-Generation Troponins in -Segment-Elevation Myocardial Infarction in the Modern Era, The - Study

  • Cediel, Germán|||0000-0001-9667-7507
  • Rueda, Ferran|||0000-0001-5464-4870
  • Garcia Garcia, Cosme|||0000-0001-6330-1677
  • Oliveras, Teresa
  • Labata, Carlos|||0000-0002-4505-0787
  • Serra Flores, Jordi
  • Núñez, Julio|||0000-0003-1672-7119
  • Bodi, Vicente|||0000-0001-6425-5828
  • Ferrer Massot, Marc|||0000-0003-0046-1301
  • Lupón, Josep|||0000-0002-5601-9611
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
In -segment-elevation myocardial infarction (), troponins are not needed for diagnosis: symptoms and data are sufficient to activate percutaneous coronary intervention. This study explored the prognostic value of new-generation troponins in a real-life cohort contemporarily treated for . We studied 1260 consecutive patients with primary treated with percutaneous coronary intervention between February 22, 2011, and August 31, 2015. We collected data on clinical characteristics and major adverse cardiovascular and cerebrovascular events () at 30 days and 1 year. Peak high-sensitivity troponin T and sensitive-contemporary troponin I levels were recorded. s occurred in 75 patients (6.1%) by day 30 and in 124 patients (10.8%) between day 31 and 1 year. A short-term (0-30 days) multivariable Cox regression analysis revealed that age, Killip-Kimball class, and left ventricular ejection fraction were independent predictors of s. In adjusted analysis, peak high-sensitivity troponin T and sensitive-contemporary troponin I were not significant (hazard ratio, 1.23 [95% confidence interval, 0.98-1.54] [ P =0.071]; and hazard ratio, 1.15 [95% confidence interval, 0.93-1.43] [ P =0.200], respectively). A long-term (31 days-1 year) multivariable Cox regression analysis revealed that age, female sex, diabetes mellitus, prior coronary artery disease, Killip-Kimball class, and left ventricular ejection fraction were statistically significantly associated with . However, peak high-sensitivity troponin T and peak sensitive-contemporary troponin I were not significantly associated with (hazard ratio, 1.03 [95% confidence interval, 0.88-1.20] [ P =0.715]; and hazard ratio, 0.99 [95% confidence interval, 0.85-1.15] [ P =0.856], respectively). In the modern era, new-generation troponins do not provide significant prognostic information for predicting clinical events in . We should reconsider the value of serial troponin measurements for risk stratification in STEMI.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations

  • Núñez, Julio|||0000-0003-1672-7119
  • Núñez, Eduardo
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Miñana, Gema|||0000-0001-8777-2588
  • Barallat, Jaume|||0000-0003-3493-5958
  • Bodi, Vicente|||0000-0001-6425-5828
  • Sanchis, Juan|||0000-0003-0797-8709
  • Aimo, Alberto|||0000-0001-9129-9519
  • Emdin, Michele
  • Lupón, Josep|||0000-0002-5601-9611
  • Husser, Oliver
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
A higher neprilysin activity has been suggested in women. In this retrospective analysis, we evaluated the association of sex and body mass index (BMI) with soluble neprilysin (sNEP) and recurrent admissions among 1021 consecutive HF outpatients. The primary and secondary endpoints were the number of HF hospitalizations and all-cause mortality, respectively. The association between sNEP with either endpoint was evaluated across sex and BMI categories (≥ 25 kg/m 2 vs. < 25 kg/m 2). Bivariate count regression (Poisson) was used, and risk estimates were expressed as incidence rates ratio (IRR). During a median follow-up of 6.65 years (percentile 25%-percentile 75%:2.83-10.25), 702 (68.76%) patients died, and 406 (40%) had at least 1 HF hospitalization. Median values of sNEP and BMI were 0.64 ng/mL (0.39-1.22), and 26.9 kg/m 2 (24.3-30.4), respectively. Left ventricle ejection fraction was < 40% in 78.9% of patients, and 28% were women. In multivariable analysis, sNEP (main effect) was positively associated with HF hospitalizations (p = 0.001) but not with mortality (p = 0.241). The predictive value of sNEP for HF hospitalizations varied non-linearly across sex and BMI categories (p -value for interaction = 0.003), with significant and positive effect only on women with BMI ≥ 25 kg/m 2 (p = 0.039). For instance, compared to men, women with sNEP of 1.22 ng/mL (percentile 75%) showed a significantly increased risk (IRRs: 1.26; 95% CI: 1.05-1.53). The interaction analysis for mortality did not support a differential prognostic effect for sNEP (p = 0.072). In conclusion, higher sNEP levels in overweight women better predicted an increased risk of HF hospitalization.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Circulating linoleic acid at the time of myocardial infarction and risk of primary ventricular fibrillation

  • Oliveras, Teresa
  • Lázaro, Iolanda|||0000-0002-6172-9845
  • Rueda, Ferran|||0000-0001-5464-4870
  • Cediel, Germán|||0000-0001-9667-7507
  • Bhatt, Deepak L.|||0000-0002-1278-6245
  • Fitó, Montserrat|||0000-0002-1817-483X
  • Madrid-Gambin, Francisco
  • Pozo, Oscar J.|||0000-0002-1735-9728
  • Harris, William S.
  • Garcia Garcia, Cosme|||0000-0001-6330-1677
  • Sala-Vila, Aleix|||0000-0002-5038-2794
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Primary ventricular fibrillation (PVF) is a major driver of cardiac arrest in the acute phase of ST-segment elevation myocardial infarction (STEMI). Enrichment of cardiomyocyte plasma membranes with dietary polyunsaturated fatty acids (PUFA) reduces vulnerability to PVF experimentally, but clinical data are scarce. PUFA status in serum phospholipids is a valid surrogate biomarker of PUFA status in cardiomyocytes within a wide range of dietary PUFA. In this nested case-control study (n = 58 cases of STEMI-driven PVF, n = 116 control non-PVF STEMI patients matched for age, sex, smoking status, dyslipidemia, diabetes mellitus and hypertension) we determined fatty acids in serum phospholipids by gas-chromatography, and assessed differences between cases and controls, applying the Benjamini-Hochberg procedure on nominal P-values to control the false discovery rate (FDR). Significant differences between cases and controls were restricted to linoleic acid (LA), with PVF patients showing a lower level (nominal P = 0.002; FDR-corrected P = 0.027). In a conditional logistic regression model, each one standard deviation increase in the proportion of LA was related to a 42% lower prevalence of PVF (odds ratio = 0.58; 95% confidence interval, 0.37, 0.90; P = 0.02). The association lasted after the inclusion of confounders. Thus, regular consumption of LA-rich foods (nuts, oils from seeds) may protect against ischemia-driven malignant arrhythmias.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Nutritional Status According to the GLIM Criteria in Patients with Chronic Heart Failure, association with Prognosis

  • Joaquín, Clara|||0000-0002-9063-4853
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Lupón, Josep|||0000-0002-5601-9611
  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Domingo, Mar|||0000-0002-2935-1272
  • Zamora, Elisabet|||0000-0001-5317-7481
  • Socias Rullan, Guillem
  • Ramos Rodas, Analia Emilce|||0000-0002-0882-1247
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Background: The Global Leadership Initiative on Malnutrition (GLIM) criteria were recently proposed to build a global consensus on the diagnostic criteria for malnutrition. This study aimed to evaluate the GLIM criteria for its prognostic significance in outpatients with heart failure (HF), and to compare them to a previous validated method, such as the Mini Nutritional Assessment (MNA). Methods: This was a post hoc observational analysis of a prospectively recruited cohort, which included 151 subjects that attended an outpatient HF clinic. At baseline, all patients completed the nutritional screening MNA short form and the nutritional assessment MNA. In a post hoc analysis, we evaluated the GLIM criteria at baseline. The outcomes were based on data from a five-year follow-up. The primary endpoint was all-cause mortality. Secondary endpoints were cardiovascular (CV) mortality and recurrent HF-related hospitalizations. We also investigated whether the GLIM criteria had better prognostic power than the MNA. Results: Abnormal nutritional status was identified in 19.8% of the patients with the GLIM criteria and in 25.1% with the MNA. In the multivariate analyses (age, sex, NYHA functional class, diabetes, and Barthel index), nutritional status assessed by the MNA, but not by the GLIM criteria, was an independent predictor of all-cause mortality, CV mortality, and recurrent HF-related hospitalizations during the five-year follow-up. Conclusions: Malnutrition assessed by MNA, but not by the GLIM criteria, was an independent predictor of all-cause mortality, CV mortality, and recurrent HF-related hospitalization in our cohort of outpatients with HF.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Long-term antibiotic therapy in patients with surgery-indicated not undergoing surgery infective endocarditis

  • Vallejo Camazon, Nuria
  • Mateu, Lourdes|||0000-0001-7223-7611
  • Cediel, Germán|||0000-0001-9667-7507
  • Escolà-Vergé, Laura|||0000-0002-5608-3090
  • Fernández Hidalgo, Nuria|||0000-0002-2115-344X
  • Gurguí, Mercè|||0000-0002-0474-3528
  • Pérez Rodriguez, María Teresa|||0000-0003-2944-8610
  • Cuervo, Guillermo|||0000-0002-7075-943X
  • Núñez Aragón, Raquel
  • Llibre, Cinta|||0000-0003-3618-9741
  • Sopena, Nieves|||0000-0001-6382-9500
  • Quesada, Maria Dolores|||0000-0001-8360-3787
  • Berastegui García, Elisabet|||0000-0002-1766-2970
  • Teis, Albert|||0000-0002-4820-0736
  • López Ayerbe, Jorge|||0009-0008-8495-0877
  • Juncà Puig, Gladys|||0000-0002-4421-5658
  • Gual-Capllonch, Francisco
  • Ferrer Sistach, Elena
  • Vivero, Ainhoa
  • Reynaga, Esteban|||0000-0002-4069-6087
  • Hernández-Pérez, María|||0000-0001-8279-7954
  • Muñoz-Guijosa, Christian|||0000-0002-0272-1704
  • Pedro Botet, Maria Luisa|||0000-0001-7252-3191
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Background: To date, there is little information regarding management of patients with infective endocarditis (IE) that did not undergo an indicated surgery. Therefore, we aimed to evaluate prognosis of these patients treated with a long-term antibiotic treatment strategy, including oral long term suppressive antibiotic treatment in five referral centres with a multidisciplinary endocarditis team. Methods: This retrospective, multicenter study retrieved individual patient-level data from five referral centres in Spain. Among a total of 1797, 32 consecutive patients with IE were examined (median age 72 years; 78% males) who had not undergone an indicated surgery, but received long-term antibiotic treatment (LTAT) and were followed by a multidisciplinary endocarditis team, between 2011 and 2019. Primary outcomes were infection relapse and mortality during follow-up. Results: Among 32 patients, 21 had IE associated with prostheses. Of the latter, 8 had an ascending aorta prosthetic graft. In 24 patients, a switch to long-term oral suppressive antibiotic treatment (LOSAT) was considered. The median duration of LOSAT was 277 days. Four patients experienced a relapse during follow-up. One patient died within 60 days, and 12 patients died between 60 days and 3 years. However, only 4 deaths were related to IE. Conclusions: The present study results suggest that a LTAT strategy, including LOSAT, might be considered for patients with IE that cannot undergo an indicated surgery. After hospitalization, they should be followed by a multidisciplinary endocarditis team.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Fatty Acid Binding Proteins 3 and 4 Predict Both All-Cause and Cardiovascular Mortality in Subjects with Chronic Heart Failure and Type 2 Diabetes Mellitus

  • Rodríguez-Calvo, Ricardo|||0000-0001-7513-0983
  • Granado-Casas, Minerva|||0000-0003-3447-5728
  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Julián, María Teresa|||0000-0003-2524-1823
  • Domingo, Mar|||0000-0002-2935-1272
  • Codina, Pau|||0000-0002-2469-5711
  • Santiago Vacas, Evelyn|||0000-0001-7511-406X
  • Cediel, Germán|||0000-0001-9667-7507
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Rossell, Joana|||0000-0003-1500-6379
  • Masana, Luis|||0000-0002-0789-4954
  • Mauricio, Didac|||0000-0002-2868-0250
  • Lupón, Josep|||0000-0002-5601-9611
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
Subjects with type 2 diabetes mellitus (T2D) are at increased risk for heart failure (HF). The cardiac-specific (FABP3) and adipose-tissue-specific (FABP4) types of the fatty acid binding proteins have been associated with both all-cause and cardiovascular (CV) mortality. The aim of this study was to explore the prognosis value of FABP3 and FABP4 in ambulatory subjects with chronic HF (CHF), with and without T2D. A prospective study involving 240 ambulatory CHF subjects was performed. Patients were followed-up for a mean of 5.78 ± 3.30 years and cause of death (if any) was recorded. Primary endpoints were defined as all-cause and CV death, and a composite endpoint that included CV death or hospitalization for HF was included as a secondary endpoint. Baseline serum samples were obtained and the serum FABP3 and FABP4 concentrations were assessed by sandwich enzyme-linked immunosorbent assay. Survival analysis was performed with multivariable Cox regressions, using Fine and Gray competing risks models when needed, to explore the prognostic value of FABP3 and FABP4 concentrations, adjusting for potential confounders. Type 2 diabetes mellitus was highly prevalent, accounting for 47.5% for total subjects with CHF. Subjects with T2D showed higher mortality rates (T2D: 69.30%; non-T2D: 50.79%, p = 0.004) and higher serum FABP3 (1829.3 (1104.9-3440.5) pg/mL vs. 1396.05 (820.3-2362.16) pg/mL, p = 0.007) and FABP4 (45.5 (27.6-79.8) ng/mL vs. 34.1 (24.09-55.3) ng/mL, p = 0.006) concentrations compared with non-T2D CHF subjects. In the whole study cohort, FABP3 was independently associated with all-cause death, and both FABP3 and FABP4 concentrations were associated with CV mortality. The predictive values of these two molecules for all-cause (FABP3: HR 1.25, 95% CI 1.09-1.44; p = 0.002. FABP4: HR 2.21, 95% CI 1.12-4.36; p = 0.023) and CV mortality (FABP3: HR 1.28, 95% CI 1.09-1.50; p = 0.002. FABP4: HR 4.19, 95% CI 2.21-7.95; p < 0.001) were only statistically significant in the subgroup of subjects with T2D. Notably, FABP4 (HR 2.07, 95% CI 1.11-3.87; p = 0.022), but not FABP3, also predicted the occurrence of the composite endpoint (death or hospitalization for HF) only in subjects with T2D. All these associations were not found in CHF subjects without T2D. Our findings support the usefulness of serum FABP3 and FABP4 concentrations as independent predictors for the occurrence of all-cause and CV mortality in ambulatory subjects with CHF with T2D.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Venous Leg Compression for Tissue Decongestion in Patients With Worsening Congestive Heart Failure

  • Civera, Jose
  • Miñana, Gema|||0000-0001-8777-2588
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Santas, Enrique
  • Sastre, Clara
  • Mollar, Anna
  • Conesa, Adriana
  • Martínez, Ana
  • Núñez, Eduardo
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Núñez, Julio|||0000-0003-1672-7119
Venous leg compression (VLC) with elastic bandages has been proposed as a potentially useful strategy for decreasing tissue congestion. We aimed to evaluate the effect of VLC on short-term changes on intravascular refill, assessed by inferior vena cava (IVC) diameter in patients with worsening heart failure (WHF) requiring parenteral furosemide. Additionally, we sought to evaluate whether early changes in IVC were related to short-term decongestion. This is a prospective study in which we included 20 consecutive ambulatory patients with WHF treated with subcutaneous furosemide and VLC for at least 72 h. The endpoints were (a) short-term changes in IVC, (b) the association between decongestion and 3-h IVC changes following VLC. Changes in continuous endpoints and their longitudinal trajectories were estimated with linear mixed regression models. All analyses were adjusted for multiple comparisons. Following administration of subcutaneous furosemide and VLC, we found a significant increase in 3-h IVC diameter (ΔIVC = 1.6 mm, CI 95%: 0.7-2.5; p < 0.001), with a greater increase in those with baseline IVC≤21 mm (2.4 vs. 0.8 mm; p < 0.001). 3-h intravascular refill (increase in IVC≥2 mm) was associated with greater decongestion (natriuresis, weight, peripheral edemas, and dyspnea) in those with baseline IVC≤21 mm but not when IVC>21 mm (p < 0.05 for all comparisons). In this cohort of patients with congestive WHF treated with subcutaneous furosemide and VLC, we found a greater increase in short-term IVC in those with IVC ≤21 mm at baseline. In this subset of patients, a 3-h increase in IVC≥2 mm was associated with greater short-term decongestion.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Acellular cardiac scaffolds enriched with MSC-derived extracellular vesicles limit ventricular remodelling and exert local and systemic immunomodulation in a myocardial infarction porcine model

  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Martínez-Falguera, Daina|||0000-0002-9439-0542
  • Teis, Albert|||0000-0002-4820-0736
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Courageux, Yvan|||0000-0002-1484-2677
  • Munizaga-Larroudé, Micaela
  • Font-Morón, Miriam|||0000-0002-4714-252X
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Rudilla, F..
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
Rationale: Extracellular vesicles (EVs) from mesenchymal stromal cell (MSC) are a potential therapy for cardiac healing after myocardial infarction (MI). Nevertheless, neither their efficient administration nor therapeutic mechanisms are fully elucidated. Here, we evaluate the preclinical efficacy of a tissue engineering approach to locally deliver porcine cardiac adipose tissue MSC-EV (cATMSC-EV) in an acute MI pig model. Methods: After MI by permanent ligation of the coronary artery, pigs (n = 24) were randomized to Untreated or treated groups with a decellularised pericardial scaffold filled with peptide hydrogel and cATMSC-EV purified by size exclusion chromatography (EV-Treated group) or buffer (Control group), placed over the post-infarcted myocardium. Results: After 30 days, cardiac MRI showed an improved cardiac function in EV-Treated animals, with significantly higher right ventricle ejection fraction (+20.8% in EV-Treated; p = 0.026), and less ventricle dilatation, indicating less myocardial remodelling. Scar size was reduced, with less fibrosis in the distal myocardium (-42.6% Col I in EV-Treated vs Untreated; p = 0.03), a 2-fold increase in vascular density (EV-Treated; p = 0.019) and less CCL2 transcription in the infarct core. EV-treated animals had less macrophage infiltration in the infarct core (-31.7% of CD163 + cells/field in EV-Treated; p = 0.026), but 5.8 times more expressing anti-inflammatory CD73 (p = 0.015). Systemically, locally delivered cATMSC-EV also triggered a systemic effect, doubling the circulating IL-1ra (p = 0.01), and reducing the PBMC rush 2d post-MI, the TNFα and GM-CSF levels at 30d post-MI, and modulating the CD73 + and CCR2 + monocyte populations, related to immunomodulation and fibrosis modulation. Conclusions: These results highlight the potential of cATMSC-EV in modulating hallmarks of ischemic injury for cardiac repair after MI.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

  • de la Fuente, Ana
  • Santisteban, Marta|||0000-0003-0625-686X
  • Lupón, Josep|||0000-0002-5601-9611
  • Aramendía, José Manuel|||0000-0002-6417-4267
  • Díaz, Agnes
  • Santaballa, Ana|||0000-0001-7763-320X
  • Hernándiz, Amparo
  • Sepúlveda, Pilar|||0000-0001-6071-7431
  • Cediel, Germán|||0000-0001-9667-7507
  • López, Begoña
  • Picazo, José María López
  • Mazo, Manuel M.|||0000-0002-6250-5579
  • Rábago, Gregorio
  • Gavira, Juan José
  • García-Bolao, Ignacio
  • Díez, Javier|||0000-0002-3414-6919
  • González, Arantxa|||0000-0001-5986-6528
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Ravassa, Susana
Left ventricular dysfunction (LVD) induced by anthracycline-based cancer chemotherapy (ACC) is becoming an urgent healthcare concern. Myocardial fibrosis (MF) may contribute to LVD after ACC. We show that elevated circulating levels of procollagen type I C-terminal propeptide (PICP, biomarker of MF) are associated with early subclinical LVD and predict later development of cardiotoxicity in patients treated with ACC. In addition, an association between PICP and LVD in patients with ACC-induced heart failure is observed. These results provide novel insights into MF as a mechanism underlying LVD after ACC, with PICP emerging as a promising tool to monitor cardiotoxicity in patients treated with ACC. Anthracycline-based cancer chemotherapy (ACC) causes myocardial fibrosis, a lesion contributing to left ventricular dysfunction (LVD). We investigated whether the procollagen-derived type-I C-terminal-propeptide (PICP): (1) associates with subclinical LVD (sLVD) at 3-months after ACC (3m-post-ACC); (2) predicts cardiotoxicity 1-year after ACC (12m-post-ACC) in breast cancer patients (BC-patients); and (3) associates with LVD in ACC-induced heart failure patients (ACC-HF-patients). Echocardiography, serum PICP and biomarkers of cardiomyocyte damage were assessed in two independent cohorts of BC-patients: CUN (n = 87) at baseline, post-ACC, and 3m and 12m (n = 65)-post-ACC; and HULAFE (n = 70) at baseline, 3m and 12m-post-ACC. Thirty-seven ACC-HF-patients were also studied. Global longitudinal strain (GLS)-based sLVD (3m-post-ACC) and LV ejection fraction (LVEF)-based cardiotoxicity (12m-post-ACC) were defined according to guidelines. BC-patients: all biomarkers increased at 3m-post-ACC versus baseline. PICP was particularly increased in patients with sLVD (interaction- p < 0.001) and was associated with GLS (p < 0.001). PICP increase at 3m-post-ACC predicted cardiotoxicity at 12m-post-ACC (odds-ratio ≥ 2.95 per doubling PICP, p ≤ 0.025) in both BC-cohorts, adding prognostic value to the early assessment of GLS and LVEF. ACC-HF-patients: PICP was inversely associated with LVEF (p = 0.004). In ACC-treated BC-patients, an early increase in PICP is associated with early sLVD and predicts cardiotoxicity 1 year after ACC. PICP is also associated with LVD in ACC-HF-patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical translation of mesenchymal stromal cell extracellular vesicles, Considerations on scientific rationale and production requisites

  • Courageux, Yvan|||0000-0002-1484-2677
  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Roura, Santiago|||0000-0003-4063-9661
The present paper is a commentary to 'Identification and characterization of hADSC - derived exosome proteins from different isolation methods ' (Huang et al. 2021; ). Given the enthusiasm for the potential of mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs), some considerations deserve attention as they move through successive stages of research and application into humans. We herein remark the prerequisite of generating that evidence ensuring a high consistency in safety, composition and biological activity of the intended MSC-EV preparations, and the suitability of disparate isolation techniques to produce efficacious EV preparations and fulfil requirements for standardized clinical-grade biomanufacturing.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Deep Learning Analyses to Delineate the Molecular Remodeling Process after Myocardial Infarction

  • Iborra Egea, Oriol|||0000-0002-7280-859X
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Rudilla, F
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Ferrer-Curriu, Gemma|||0000-0002-2651-649X
  • Segú-Vergés, Cristina|||0000-0002-8215-872X
  • Mellado-Bergillos, Araceli
  • Gomez-Puchades, Pol
  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Specific proteins and processes have been identified in post-myocardial infarction (MI) pathological remodeling, but a comprehensive understanding of the complete molecular evolution is lacking. We generated microarray data from swine heart biopsies at baseline and 6, 30, and 45 days after infarction to feed machine-learning algorithms. We cross-validated the results using available clinical and experimental information. MI progression was accompanied by the regulation of adipogenesis, fatty acid metabolism, and epithelial-mesenchymal transition. The infarct core region was enriched in processes related to muscle contraction and membrane depolarization. Angiogenesis was among the first morphogenic responses detected as being sustained over time, but other processes suggesting post-ischemic recapitulation of embryogenic processes were also observed. Finally, protein-triggering analysis established the key genes mediating each process at each time point, as well as the complete adverse remodeling response. We modeled the behaviors of these genes, generating a description of the integrative mechanism of action for MI progression. This mechanistic analysis overlapped at different time points; the common pathways between the source proteins and cardiac remodeling involved IGF1R, RAF1, KPCA, JUN, and PTN11 as modulators. Thus, our data delineate a structured and comprehensive picture of the molecular remodeling process, identify new potential biomarkers or therapeutic targets, and establish therapeutic windows during disease progression.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Circulating virome and inflammatory proteome in patients with ST-elevation myocardial infarction and primary ventricular fibrillation

  • Oliveras, Teresa
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Garcia Garcia, Cosme|||0000-0001-6330-1677
  • Cserkóová, Adriana
  • Rueda, Ferran|||0000-0001-5464-4870
  • Labata, Carlos|||0000-0002-4505-0787
  • Ferrer Vinardel, Marc|||0000-0002-1283-8578
  • Montero, Santiago|||0000-0002-0984-3472
  • El Ouaddi, Nabil|||0000-0002-5980-8915
  • Martínez, Maria José
  • Roura, Santiago|||0000-0003-4063-9661
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Primary ventricular fibrillation (PVF) is a life-threatening complication of ST-segment elevation myocardial infarction (STEMI). It is unclear what roles viral infection and/or systemic inflammation may play as underlying triggers of PVF, as a second hit in the context of acute ischaemia. Here we aimed to evaluate whether the circulating virome and inflammatory proteome were associated with PVF development in patients with STEMI. Blood samples were obtained from non-PVF and PVF STEMI patients at the time of primary PCI, and from non-STEMI healthy controls. The virome profile was analysed using VirCapSeq-VERT (Virome Capture Sequencing Platform for Vertebrate Viruses), a sequencing platform targeting viral taxa of 342,438 representative sequences, spanning all virus sequence records. The inflammatory proteome was explored with the Olink inflammation panel, using the Proximity Extension Assay technology. After analysing all viral taxa known to infect vertebrates, including humans, we found that non-PVF and PVF patients only significantly differed in the frequencies of viruses in the Gamma-herpesvirinae and Anelloviridae families. In particular, most showed a significantly higher relative frequency in non-PVF STEMI controls. Analysis of systemic inflammation revealed no significant differences between the inflammatory profiles of non-PVF and PVF STEMI patients. Inflammatory proteins associated with cell adhesion, chemotaxis, cellular response to cytokine stimulus, and cell activation proteins involved in immune response (IL6, IL8 CXCL-11, CCL-11, MCP3, MCP4, and ENRAGE) were significantly higher in STEMI patients than non-STEMI controls. CDCP1 and IL18-R1 were significantly higher in PVF patients compared to healthy subjects, but not compared to non-PVF patients. The circulating virome and systemic inflammation were not associated with increased risk of PVF development in acute STEMI. Accordingly, novel strategies are needed to elucidate putative triggers of PVF in the setting of acute ischaemia, in order to reduce STEMI-driven sudden death burden.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

LRP1-Mediated AggLDL Endocytosis Promotes Cholesteryl Ester Accumulation and Impairs Insulin Response in HL-1 Cells

  • Actis Dato, Virginia|||0000-0002-9071-8045
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Vazquez, M.
  • Bonacci, G.
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Chiabrando, G.A.
The cardiovascular disease (CVD) frequently developed during metabolic syndrome and type-2 diabetes mellitus is associated with increased levels of aggregation-prone small LDL particles. Aggregated LDL (aggLDL) internalization is mediated by low-density lipoprotein receptor-related protein-1 (LRP1) promoting intracellular cholesteryl ester (CE) accumulation. Additionally, LRP1 plays a key function in the regulation of insulin receptor (IR) and glucose transporter type 4 (GLUT4) activities. Nevertheless, the link between LRP1, CE accumulation, and insulin response has not been previously studied in cardiomyocytes. We aimed to identify mechanisms through which aggLDL, by its interaction with LRP1, produce CE accumulation and affects the insulin-induced intracellular signaling and GLUT4 trafficking in HL-1 cells. We demonstrated that LRP1 mediates the endocytosis of aggLDL and promotes CE accumulation in these cells. Moreover, aggLDL reduced the molecular association between IR and LRP1 and impaired insulin-induced intracellular signaling activation. Finally, aggLDL affected GLUT4 translocation to the plasma membrane and the 2-NBDG uptake in insulin-stimulated cells. We conclude that LRP1 is a key regulator of the insulin response, which can be altered by CE accumulation through LRP1-mediated aggLDL endocytosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Association of circulating microRNAs with coronary artery disease and usefulness for reclassification of healthy individuals, The REGICOR study

  • Degano, Irene R.|||0000-0003-1914-6934
  • Camps-Vilaró, Anna|||0000-0001-9644-8421
  • Subirana, Isaac|||0000-0003-1676-0197
  • García-Mateo, Nadia
  • Cidad, Pilar
  • Muñoz Aguayo, Daniel|||0000-0001-8173-0168
  • Puigdecanet, Eulàlia|||0000-0001-6067-9332
  • Nonell, Lara|||0000-0002-8538-8213
  • Vila-Domènech, Joan Salvador|||0000-0002-0413-9291
  • Crepaldi, Felipe Mingorance|||0000-0002-8500-1162
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Pérez-García, María Teresa|||0000-0001-8540-8117
  • Elosua, Roberto|||0000-0001-8235-0095
  • Fitó, Montserrat|||0000-0002-1817-483X
  • Marrugat, Jaume|||0000-0003-3320-554X
Risk prediction tools cannot identify most individuals at high coronary artery disease (CAD) risk. Oxidized low-density lipoproteins (oxLDLs) and microRNAs are actively involved in atherosclerosis. Our aim was to examine the association of CAD and oxLDLs-induced microRNAs, and to assess the microRNAs predictive capacity of future CAD events. Human endothelial and vascular smooth muscle cells were treated with oxidized/native low-density lipoproteins, and microRNA expression was analyzed. Differentially expressed and CAD-related miRNAs were examined in serum samples from (1) a case-control study with 476 myocardial infarction (MI) patients and 487 controls, and (2) a case-cohort study with 105 incident CAD cases and 455 randomly-selected cohort participants. MicroRNA expression was analyzed with custom OpenArray plates, log rank tests and Cox regression models. Twenty-one microRNAs, two previously undescribed (hsa-miR-193b-5p and hsa-miR-1229-5p), were up- or down-regulated upon cell treatment with oxLDLs. One of the 21, hsa-miR-122-5p, was also upregulated in MI cases (fold change = 4.85). Of the 28 CAD-related microRNAs tested, 11 were upregulated in MI cases -1 previously undescribed (hsa-miR-16-5p)-, and 1/11 was also associated with CAD incidence (adjusted hazard ratio = 0.55 (0.35-0.88)) and improved CAD risk reclassification, hsa-miR-143-3p. We identified 2 novel microRNAs modulated by oxLDLs in endothelial cells, 1 novel microRNA upregulated in AMI cases compared to controls, and one circulating microRNA that improved CAD risk classification.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Circulating non-coding RNAs in biomarker-guided cardiovascular therapy, A novel tool for personalized medicine?

  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Vea Badenes, Angela|||0000-0001-7856-6635
  • Bär, Christian
  • Fiedler, Jan
  • Couch, Liam S.
  • Brotons, Carlos|||0000-0001-9388-6581
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Thum, Thomas|||0000-0003-4360-1511
Current clinical guidelines emphasize the unmet need for technological innovations to guide physician decision-making and to transit from conventional care to personalized cardiovascular medicine. Biomarker-guided cardiovascular therapy represents an interesting approach to inform tailored treatment selection and monitor ongoing efficacy. However, results from previous publications cast some doubts about the clinical applicability of biomarkers to direct individualized treatment. In recent years, the non-coding human transcriptome has emerged as a new opportunity for the development of novel therapeutic strategies and biomarker discovery. Non-coding RNA (ncRNA) signatures may provide an accurate molecular fingerprint of patient phenotypes and capture levels of information that could complement traditional markers and established clinical variables. Importantly, ncRNAs have been identified in body fluids and their concentrations change with physiology and pathology, thus representing promising non-invasive biomarkers. Previous publications highlight the translational applicability of circulating ncRNAs for diagnosis and prognostic stratification within cardiology. Numerous independent studies have also evaluated the potential of the circulating non-coding transcriptome to predict and monitor response to cardiovascular treatment. However, this field has not been reviewed in detail. Here, we discuss the state-of-the-art research into circulating ncRNAs, specifically microRNAs and long non-coding RNAs, to support clinical decision-making in cardiovascular therapy. Furthermore, we summarize current methodological and conceptual limitations and propose future steps for their incorporation into personalized cardiology. Despite the lack of robust population-based studies and technical barriers, circulating ncRNAs emerge as a promising tool for biomarker-guided therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Serum circular RNAs act as blood-based biomarkers for hypertrophic obstructive cardiomyopathy

  • Sonnenschein, Kristina
  • Wilczek, Adriana Luisa
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Pfanne, Angelika
  • Derda, Anselm Arthur
  • Zwadlo, Carolin
  • Bavendiek, Udo
  • Bauersachs, Johann|||0000-0002-9341-117X
  • Fiedler, Jan
  • Thum, Thomas|||0000-0003-4360-1511
Hypertrophic cardiomyopathy (HCM) is one of the most common hereditary heart diseases and is associated with a high risk of sudden cardiac death. HCM is characterized by pronounced hypertrophy of cardiomyocytes, fiber disarray and development of fibrosis and can be divided into a non-obstructive (HNCM) and obstructive form (HOCM) therefore requiring personalized therapeutic therapies. In the present study, we investigated the expression patterns of several circulating circular RNAs (circRNAs) as potential biomarkers in patients with HCM. We included 64 patients with HCM and 53 healthy controls to the study and quantitatively measured the expression of a set of circRNAs already known to be associated with cardiac diseases (circDNAJC6) and/or being highly abundant in blood (circTMEM56 and circMBOAT2). Abundancy of circRNAs was then correlated to relevant clinical parameters. Serum expression levels of circRNAs DNAJC6, TMEM56 and MBOAT2 were downregulated in patients with HCM. The inverse association between circRNA levels and HCM remained unchanged even after adjusting for confounding factors. All circRNAs, evaluated separately or in combination, showed a robust discrimination capacity when comparing control subjects with HCM, HNCM or HOCM patients (AUC from 0.722 to 0.949). Two circRNAs, circTMEM56 and circDNAJC6, significantly negatively correlated with echocardiographic parameters for HOCM. Collectively, circulating circRNAs DNAJC6, TMEM56 and MBOAT2 can distinguish between healthy and HCM patients. In addition, circTMEM56 and circDNAJC6 could serve as indicators of disease severity in patients with HOCM. Thus, circRNAs emerge as novel biomarkers for HCM facilitating the clinical decision making in a personalized manner.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Leukocyte telomere length correlates with hypertrophic cardiomyopathy severity

  • Chatterjee, Shambhabi
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Derda, Anselm Arthur
  • Schimmel, Katharina
  • Sonnenschein, Kristina
  • Bavendiek, Udo
  • Bauersachs, Johann|||0000-0002-9341-117X
  • Bär, Christian
  • Thum, Thomas|||0000-0003-4360-1511
Telomere length is a marker of biological aging. Short leukocyte telomere length has been associated with various conditions including cardiovascular disorders. Here, we evaluated if patients with hypertrophic cardiomyopathy have altered leukocyte telomere length and whether this is associated with disease severity. A quantitative polymerase chain reaction-based method was used to measure peripheral blood leukocyte telomere length in 59 healthy control subjects and a well-characterized cohort of 88 patients diagnosed with hypertrophic cardiomyopathy: 32 patients with non-obstructive cardiomyopathy (HNCM) and 56 patients with obstructive cardiomyopathy (HOCM). We observed shorter leukocyte telomeres in both HNCM and HOCM patients compared to healthy controls. Furthermore, leukocyte telomere length was inversely associated with HCM even after adjusting for age and sex. Telomere length of HOCM patients was also inversely correlated with left ventricular outflow tract obstruction. Therefore, HOCM patients were categorized by tertiles of telomere length. Patients in the first tertile (shortest telomeres) had a significantly increased left ventricular posterior wall thickness at end-diastole and higher left ventricular outflow tract gradients, whereas the left ventricular end-diastolic diameter was lower compared with patients in the second and third tertile. In summary, telomere length is associated with the severity of the disease in the HOCM subtype.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Local administration of porcine immunomodulatory, chemotactic and angiogenic extracellular vesicles using engineered cardiac scaffolds for myocardial infarction

  • Moron-Font, Miriam
  • Clos-Sansalvador, Marta
  • Calle, Alexandra
  • Morancho Retana, Anna
  • Rosell Novel, Anna
  • Monguió-Tortajada, Marta
  • Prat-Vidal, Cristina
  • Gastelurrutia, Paloma
Ingeniería de tejido cardíaco; Exosomas; Infiltración, Enginyeria de teixits cardíacs; Exosomes; Infiltració, Cardiac tissue engineering; Exosomes; Infiltration, The administration of extracellular vesicles (EV) from mesenchymal stromal cells (MSC) is a promising cell-free nanotherapy for tissue repair after myocardial infarction (MI). However, the optimal EV delivery strategy remains undetermined. Here, we designed a novel MSC-EV delivery, using 3D scaffolds engineered from decellularised cardiac tissue as a cell-free product for cardiac repair. EV from porcine cardiac adipose tissue-derived MSC (cATMSC) were purified by size exclusion chromatography (SEC), functionally analysed and loaded to scaffolds. cATMSC-EV markedly reduced polyclonal proliferation and pro-inflammatory cytokines production (IFNγ, TNFα, IL12p40) of allogeneic PBMC. Moreover, cATMSC-EV recruited outgrowth endothelial cells (OEC) and allogeneic MSC, and promoted angiogenesis. Fluorescently labelled cATMSC-EV were mixed with peptide hydrogel, and were successfully retained in decellularised scaffolds. Then, cATMSC-EV-embedded pericardial scaffolds were administered in vivo over the ischemic myocardium in a pig model of MI. Six days from implantation, the engineered scaffold efficiently integrated into the post-infarcted myocardium. cATMSC-EV were detected within the construct and MI core, and promoted an increase in vascular density and reduction in macrophage and T cell infiltration within the damaged myocardium. The confined administration of multifunctional MSC-EV within an engineered pericardial scaffold ensures local EV dosage and release, and generates a vascularised bioactive niche for cell recruitment, engraftment and modulation of short-term post-ischemic inflammation., This work was supported in part by grants from Fundació la Marató de TV3 (201516-10, 201502-30), the PERIS (SLT002/16/00234) and SGR programmes (2017-SGR-301 REMAR Group, 2017-SGR-1427 and 2017-SGR-483 ICREC Group) from the Generalitat de Catalunya, the Spanish Ministry of Economy and Competitiveness-MICINN (SAF2017-84324-C2-1-R; PID2019-110137RB-I00; PID2019-107145RB-I00), Instituto de Salud Carlos III (PI17/01487, PIC18/00014, ICI19/00039, PI18/00256, PI18/01227, and ICI20/00135), ISCIII-REDinREN (RD16/0009 Feder Funds), Red de Terapia Celular-TerCel (RD16/0011/0006), CIBER Cardiovascular (CB16/11/00403) projects as a part of the Plan Nacional de I + D + I, and it was co-funded by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER), AGAUR (2019PROD00122), Sociedad Española de Cardiología, Societat Catalana de Cardiologia, PCMR[C] and EoI Collaborative Projects on Regenerative Medicine 2019, and Institut Català de Salut (ICS). PG is sponsored by the PERIS (SLT002/16/00209) from the Generalitat de Catalunya. AR is supported by the Miguel Servet program (CPII15/00003) and research grants (PI16/00981) from the Instituto de Salud Carlos III, and co-financed by the European Regional Development Fund. FEB is a researcher from Fundació Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, supported by the Health Department of the Catalan Government (Generalitat de Catalunya).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience

  • Vives Armengol, Joaquim
  • Coll, Ruth
  • Gálvez-Montón, Carolina
  • Prat-Vidal, Cristina
  • Gastelurrutia, Paloma
  • Bayes-Genis, Antoni
Medicament de teràpia avançada; Medicament en investigació; Translacional (regulació), Medicamento de terapia avanzada; Medicamento en investigación; Traslacional (regulación), Advanced therapy medicinal product; Investigational medicinal product; Translational (regulation), A systematic and ordered product development program, in compliance with current quality and regulatory standards, increases the likelihood of yielding a successful advanced therapy medicinal product (ATMP) for clinical use as safe and effective therapy. As this is a novel field, little accurate information is available regarding the steps to be followed, and the information to be produced to support the development and use of an ATMP. Notably, successful clinical translation can be somewhat cumbersome for academic researchers. In this article, we have provided a summary of the available information, supported by our experience in Spain throughout the development of an ATMP for myocardial infarction, from the pre-clinical stage to phase I clinical trial approval., This work was supported by the Spanish Cell Therapy Network (TerCel) [RD16/0011/0006 and RD16/0011/0028]; and CIBER Cardiovascular [CB16/11/00403] projects, as a part of the National R&D&I Plan, and was co-funded by the ISCIII-Sub-Directorate General for Research Assessment and Promotion and the European Regional Development Fund (ERDF); the Government of Catalonia: Agency for Management of University and Research Grants (AGAUR) [2017-SGR-483 and 2017-SGR-719], PERIS Program (Health Department) [SLT002/16/00234 and SLT002/16/00209] and CERCA Program; La Caixa Banking Foundation; grants from the Spanish Ministry of Science, Innovation and Universities (MICINN) [SAF2017-84324-C2-1-R]; Institute of Health Carlos III (ISCIII) [PI18/00256, PIC18/00014, ICI19/00039, and PI19/01788], and cofunded by European Union (ERDF/ESF) - A way to build Europe. This work has also been funded by the Sociedad Española de Cardiología and by the Call for Expression of Interest (EoI) for Collaborative Projects on Regenerative Medicine 2019 of Center for Regenerative Medicine of Barcelona (CMR[B]). The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.